2021. RFLSP.Russian.Finnish.Life.Science.Industry.EN

This publication was developed in the framework of the project Russian-Finnish Life Science Park. The project is funded

by the European Union, the Russian Federation and the Republic of Finland in the framework of South-East Finland-

Russia CBC Programme 2014-2020. The project is executed by Saint Petersburg Technopark (RUS) (Lead partner) and

Municipality of the city of Kotka (FIN).

Russian-Finnish Life Science Park’s aim is to contribute to the economic development and global competitiveness of

Finland and Russia by positioning the cross-border region as an emerging life science destination by establishment of

cross-border life science parks as well as by strengthening internationalization of SMEs by fostering technology

transfer and R&D cooperation including reboot of cooperation ties between academia and authorities.

2

RUSSIAN-FINNISH LIFE SCIENCE INDUSTRY

Research and export directory

CONTENTS

INTRODUCTION ....................................................................................................................... 7

1 PART 1: MARKET RESEARCH ....................................................................................... 8

1.1 Industry overview .............................................................................................................................. 8

1.1.1 Overview of the Russian pharmaceutical market ............................................................................... 8

1.1.2 Commercial segment of the Russian pharmaceutical market ........................................................... 16

1.1.3 Drug reimbursement segment ......................................................................................................... 18

1.1.4 Segment of purchases of drugs for needs of healthcare institutions ............................................... 20

1.1.5 Dietary supplements segment .......................................................................................................... 22

1.1.6 Export of Russian pharmaceutical products ..................................................................................... 23

1.1.7 Manufacturing and export of pharmaceutical products in St.Petersburg and Leningrad Region .... 25

1.1.8 Government policy and support for the pharmaceutical industry in Russia ..................................... 27

1.2 Key trends ....................................................................................................................................... 31

1.2.1 Key development factors and events of the Russian pharmaceutical market ................................... 31

1.2.2 Problems and barriers of the Russian pharmaceutical market ......................................................... 33

1.2.3 Forecasts for the development of the Russian pharmaceutical market ............................................ 35

1.3 Educational institutions .................................................................................................................. 37

1.3.1 Saint Petersburg State Chemical Pharmaceutical University ............................................................ 37

1.3.2 The Pavlov First Saint Petersburg State Medical University ............................................................. 38

1.3.3 North-Western State Medical University named after I.I. Mechnikov .............................................. 40

1.3.4 Military Medical Academy named after S. M. Kirov .......................................................................... 42

1.3.5 Saint-Petersburg State Pediatric Medical University ........................................................................ 43

1.3.6 Saint-Petersburg State Institute of Technology ............................................................................... 44

1.3.7 Peter the Great St. Petersburg Polytechnic University ..................................................................... 46

1.3.8 Pharmaceutical Technical School of the St. Petersburg State Chemical-Pharmaceutical University . 47

1.3.9 Saint-Petersburg Medico-Social Institute ......................................................................................... 48

1.4 Scientific institutions ...................................................................................................................... 49

1.4.1 All-Russian Research Institute of Food Additives ............................................................................. 49

1.4.2 Almazov National Medical Research Centre ..................................................................................... 50

1.4.3 Group of scientific research institutes .............................................................................................. 51

1.4.4 Institute of Cytology RAS ................................................................................................................. 52

1.4.5 Institute of macromolecular compounds RAS ................................................................................... 53

1.4.6 Kashkin Research Institute of Medical Mycology ............................................................................. 54

1.4.7 Regional Engineering Centre for microreactor synthesis of active pharmaceutical ingredients ...... 55

1.4.8 Research Institute of Hygiene, Occupational Pathology and Human Ecology .................................. 56

1.4.9 Saint-Petersburg Scientific Research Institute of Vaccines and Serums ........................................... 57

1.4.10 Saint-Petersburg Pasteur Institute ................................................................................................... 58

1.4.11 Scientific and Clinical Center of Toxicology named after academician S.N. Golikov ......................... 59

1.4.12 Smorodintsev Research Institute of Influenza .................................................................................. 61

1.4.13 State Research Institute of Highly Pure Biopreparations ................................................................. 63

1.4.14 V. M. Gorbatov Federal Research Center for Food Systems .............................................................. 64



3

1.5 Events .............................................................................................................................................. 66

1.5.1 Events calendar ................................................................................................................................ 66

1.5.2 International events ......................................................................................................................... 67

1.5.3 National events ................................................................................................................................ 77

1.6 Clusters and associations ................................................................................................................ 80

1.6.1 Association of pharmaceutical manufacturers of Eurasian Economic Union .................................... 80

1.6.2 Union of Medical and Pharmaceutical Projects. XXI Century ............................................................ 81

1.6.3 Cluster of medical, environmental instrumentation and biotechnology .......................................... 82

1.6.4 Professional Association of Pharmaceutical Workers ....................................................................... 83

1.7 Cases and success stories ................................................................................................................. 84

1.7.1 BIOCAD ............................................................................................................................................ 84

1.7.2 CYTOMED ......................................................................................................................................... 84

1.7.3 BIOPHARMOS ................................................................................................................................... 85

1.8 Information sources ........................................................................................................................ 86

1.8.1 Strategic planning documents .......................................................................................................... 86

1.8.2 Legislative acts ................................................................................................................................. 86

1.8.3 Statistics ........................................................................................................................................... 87

1.8.4 Research and reviews ....................................................................................................................... 87

2 PART 2: EXPORT DIRECTORY ..................................................................................... 89

2.1 ACTICOMP ........................................................................................................................................ 89

2.2 ALKOR BIO ....................................................................................................................................... 90

2.3 ALLOPHARM .................................................................................................................................... 91

2.4 AMBER ............................................................................................................................................. 92

2.5 ASSOCIATION OF MEDICINE AND ANALYTICS ................................................................................... 93

2.6 AVENA .............................................................................................................................................. 94

2.7 BALTPHARMA ................................................................................................................................... 95

2.8 BELKOZIN ......................................................................................................................................... 96

2.9 BIC ................................................................................................................................................... 97

2.10 BIOCAD ............................................................................................................................................ 98

2.11 BIOFABRIKA ..................................................................................................................................... 99

2.12 BIOPHARMOS ................................................................................................................................ 100

2.13 BIOSURF ......................................................................................................................................... 101

2.14 BIOTECH ......................................................................................................................................... 102

4



2.15 BIOVITRUM .................................................................................................................................... 103

2.16 CYTOMED ....................................................................................................................................... 104

2.17 DIOD .............................................................................................................................................. 105

2.18 EKVUS ............................................................................................................................................ 106

2.19 ELEST .............................................................................................................................................. 107

2.20 FARMAKOGEN ................................................................................................................................ 108

2.21 FARMAMED.RF ............................................................................................................................... 109

2.22 FRAMEBIOTEK ................................................................................................................................ 110

2.23 GEMATEK ....................................................................................................................................... 111

2.24 GEROPHARM .................................................................................................................................. 112

2.25 GOMEOFARM ................................................................................................................................. 113

2.26 GROTEX .......................................................................................................................................... 114

2.27 GRUNDLAGE ................................................................................................................................... 115

2.28 HARMS ........................................................................................................................................... 116

2.29 KEM ................................................................................................................................................ 117

2.30 LEKKER .......................................................................................................................................... 118

2.31 MEDPOLYMER ................................................................................................................................ 119

2.32 NEPHRON ...................................................................................................................................... 120

2.33 NICF ............................................................................................................................................... 121

2.34 NIKA ............................................................................................................................................... 122

2.35 OMEGA PHARMA ............................................................................................................................ 123

2.36 PHARM. ASSOCIATION NAMED FOR PASTER .................................................................................. 124

2.37 PHARMA GEN ................................................................................................................................. 125

2.38 PHARMA VAM ................................................................................................................................ 126

2.39 PHARMACEUTICAL FACTORY OF ST. PETERSBURG ......................................................................... 127

2.40 PHARMAKOR PRODUCTION ........................................................................................................... 128

2.41 PHARMASYNTEZ-NORD .................................................................................................................. 129



5

2.42 PHARM-HOLDING ........................................................................................................................... 130

2.43 PHARMPROJECT ............................................................................................................................ 131

2.44 PHARMSYNTHEZ ............................................................................................................................ 132

2.45 POLYSAN ........................................................................................................................................ 133

2.46 PPDP .............................................................................................................................................. 134

2.47 RADUGA LAKHTA ............................................................................................................................ 135

2.48 RESEARCH INSTITUTE OF INNOVATIVE TECHNOLOGIES AND MATERIALS ...................................... 136

2.49 SAMSON-MED ................................................................................................................................ 137

2.50 SEVERNAIA ZVEZDA ........................................................................................................................ 138

2.51 SIBENZYME .................................................................................................................................... 139

2.52 VITAL DEVELOPMENT CORPORATION ............................................................................................ 140

2.53 WERTEKS ........................................................................................................................................ 141

6



INTRODUCTION

In the last few years, including the dramatic for the global economy year 2020, the Russian

pharmaceutical and biotechnology industry has shown stable positive dynamics and can

rightfully be considered as one of the drivers of innovative development of the national

economy and healthcare.

Pharmaceutical production indices of the Russian Federation in 2019-2020 showed growth in

terms of the production of pharmaceutical substances as well as that of drugs and materials

used for medical purposes. Russian pharmaceutical market in the period from 2016 to 2019

grew annually by an average of 6.6% in ruble terms, with an even higher increase in 2020 –

9.8%.

At the same time, in the global pharmaceutical market, the share of the Russian market, one

of the top ten pharmaceutical markets worldwide, is relatively small – about 2.2%. In terms of

sales per capita, Russia ranks only 30th in the world. Despite the fact that the Russian

pharmaceutical industry is currently underrepresented in international markets, Russian

enterprises are consistently increasing their export volumes.

Strong dependence on imports is one of the key features of the Russian pharmaceutical

market: more than 80% of Russian drugs are currently produced using imported substances.

At the same time, in 2020, the industry demonstrated a decrease in imports along with an

increase in the export of pharmaceutical products.

According to the draft of the Strategy for the Development of the Pharmaceutical Industry

"Pharma-2030" (currently under development), the projected market capacity, taking into

account the financial and economic situation, may amount to RUB 5 trillion by 2030 in

consumer prices, while the volume of export of medicines, in case of implementation of

support measures, may reach USD 3,800 million. The achievement of this ambitious goal may

be facilitated by such factors as expiration in 2019-2022 of patent protection terms for many

original biological products, as well as the development of the segment of innovative drugs

in narrow therapeutic niches.

At the same time, support programs, at the stages of their formation and implementation,

should take into account high investment risks that export-oriented companies bear, and

should also focus on raising the level of local producers’ competence, stimulating them to

create intellectual property items and facilitating protection of these items in the foreign

markets.

The key vectors in the Russian pharmaceutical industry such as the development of import

substitution, localization and export of domestic pharmaceutical products open up broad

prospects for the development of international cooperation in the sphere of life science and

biotechnology.



7

1 PART 1: MARKET RESEARCH

1.1 Industry overview

1.1.1 Overview of the Russian pharmaceutical market

Today, the pharmaceutical industry in Russia is one of the drivers of innovative development

of the national economy and healthcare and has been demonstrating steady growth in recent

years. Even in 2020, which was extremely dramatic for the global economy, the Russian

pharmaceutical market experienced high sales dynamics.

According to DSM Group, 1 the Russian pharmaceutical market in the period from 2016 to 2019

grew annually by an average of 6.6% in ruble terms. At the same time, in 2020 the Russian

pharmaceutical market showed an increase of 9.8% instead of the projected 5-6%, the market

volume reached RUB 2,040 billion.

Pharmaceutical market dynamics, RUB bln

1 640 1 695

1 858

2 040

2017 2018 2019 2020

Source: DSM Group

The growth of the dollar and euro rates in March 2020 led to the fact that in dollar and euro

terms the market volume did not grow. So, in dollar terms in 2020, the volume amounted to

USD 29 billion, which is only 0.2% higher than in 2019. In euros, due to the higher growth of

the exchange rate – by 11%, the market dynamics turned out to be negative: -1.6%.

1

Hereinafter, the statistics of the pharmaceutical market of the Russian Federation is given according to the annual

analytical reports of the DSM Group agency for 2017-2020.

8



Pharmaceutical market dynamics,

USD bln

Pharmaceutical market dynamics,

EUR bln

28

27

29 29

25

23

25 25

2017 2018 2019 2020

Source: DSM Group

2017 2018 2019 2020

Source: DSM Group

Pharmaceutical production indices of the Russian Federation in 2019-2020 also show steady

growth (127.4 in 2019; 123.2 in 2020) both in terms of the production of pharmaceutical

substances and of the production of medicinal products and materials used for medical

purposes. 2

Activity code

according to

OKVED2 3

Pharmaceutical production indices of the Russian Federation,

% over the previous year

Name of the activity according to OKVED2 2018 2019 2020

21 Production of medicines and materials used for

medical purposes

101.1 127.4 123.2

21.1 Production of pharmaceutical substances 184.7 159.3 117.5

21.2 Production of medicinal products and materials

used for medical purposes

Source: Federal State Statistics Service (Rosstat)

98.9 125.9 123.5

According to the National Rating Agency 4 (hereinafter – NRA), despite the positive dynamics

of the Russian pharmaceutical market and the fact that Russia is one of the ten largest

pharmaceutical markets, its share in the world pharmaceutical market is quite small – about

2.2%. In terms of sales per capita, Russia ranks only 30th in the world. At the end of 2019, per

capita sales of pharmaceutical products in Russia amounted to USD 194, while the average for

the countries in the top 30 is USD 462.

2

According to Federal State Statistics Service (Rosstat)

3

Russian National Classifier of Types of Economic Activity

4

National Rating Agency. Analytical survey “Pharmaceutical market of the Russian Federation – will the state help us?”

of July 2020.



9

The Russian pharmaceutical market is highly dependent on imports. According to the Federal

Customs Service, Russia is a net importer of medicines: by the end of 2020, the share of

exports from Russia in the total foreign trade turnover of pharmaceutical products is only

9%. In 2019, Russia imported pharmaceutical products worth USD 14.1 billion (an increase by

one third compared to 2018). In 2020, there is a decrease in imports to USD 10.8 billion. The

volume of Russian exports of pharmaceutical products in 2019 amounted to USD 850 million,

in 2020 – to USD 1 058 million (+ 24.54%). Thus, in 2020, there is a decrease in imports along

with an increase in exports of pharmaceutical products.

Localization in the Russian Federation of foreign manufacturers interested in gaining

advantages when participating in tenders and selling their products through preferential

public procurement programs leads to the fact that the import of pharmaceutical substances

for the production of original drugs and generics is growing very fast. According to the NRA,

more than 80% of Russian medicinal products are currently produced using imported

substances. In the period from 2016 to 2019 import of pharmaceutical substances increased

to 2.3 times its value in US dollars and to 1.5 times its value by volume.

The Russian pharmaceutical market consists of two key segments: commercial drugs segment

and public one. The commercial segment represents pharmacy sales of medicinal and

parapharmaceutical products. The public sector includes hospital procurement, drug

reimbursement programs (including the High-Cost ICD Program and the Essential Drug

Coverage program) and regional benefits programs.

According to DSM Group, in 2020, along with high dynamics in the commercial segment, the

growth was largely provided by the segment of government procurement of medicines. The

most significant increase in 2020 was in the purchases of drugs for healthcare institutions.

The main growth was due to the “Fight Cancer” program and the federal heart disease

project launched in 2020.

In physical terms, the consumption of pharmaceuticals in 2020 decreased by 4%, the volume

of drug sales amounted to 6.02 billion units. The negative dynamics affects both the

commercial segment and the segment of hospital purchases.

10



Pharmaceutical market capacity

RUB bln in consumer prices

Pharmaceutical market capacity

mln packages

1 858

577

262

2 040

634

279

6 266

6 018

954

841

192 175

5 120 5 002

1 020 1 128

2019 2020

2019 2020

Public procurement + High-Cost ICD + Essential

Drug Coverage + Regional Drug Coverage

Commercial segment of parapharmaceuticals

Commercial segment of medicinal products

Hospital purchases

Pharmaceutical benefits (High-Cost ICD + Essential

Drug Coverage + Regional Drug Coverage)

Commercial segment of medicinal products

Source: DSM Group

Source: DSM Group

The share of imported medicinal products in the market at the end of 2020 amounted to

56.3% in rubles and 31.4% in units. The share of localized drugs in the market is steadily

growing from year to year being driven, among other things, by localization and import

substitution. In 2020, this process stopped due to an increase in funding for state programs

(the national program on cancer and the allocation of additional funding for High-Cost ICD

Program): in these areas, drugs are mainly imported. In physical terms, in 2020, there was a

decrease in sales of both made-in-Russia drugs (-4%) and foreign ones (-3%). In ruble terms,

localized drugs showed an increase of 13%, while imported drugs – by 8%.



11

Imported/localized drugs sales ratio,

RUB

Imported/localized drugs sales

ratio, packages

70% 70% 70%

56,3%

38% 39% 39,5% 31,4%

30% 30% 30%

43,7%

62% 61% 60,5% 68,6%

2017 2018 2019 2020

2017 2018 2019 2020

Localized drugs

Imported drugs

Localized drugs

Imported drugs

Source: DSM Group

Source: DSM Group

By the type of dispensing, the ratio in 2020 varied in favor of over-the-counter drugs (OTC).

Prescription (Rx) drugs currently account for about 67% in monetary terms. But due to the

lower price, OTC drugs prevail in physical terms (54.9%).

OTC drugs are mainly sold via pharmacies (about 97% in rubles of the general volume of OTC

drugs). In the state segment, on the contrary, Rx-drugs prevail – they account for more than

90% of the tender purchases volume.

12



OTC/RX drug sales ratio,

RUB

OTC/RX drug sales ratio,

packages

64% 64% 67,3% 66,8%

43% 44% 44,4% 45,1%

36% 36% 32,7% 33,2%

2017 2018 2019 2020

Rx (prescription drugs)

OTC (over-the-counter drugs)

Source: DSM Group

57% 56% 55,6% 54,9%

2017 2018 2019 2020

Rx (prescription drugs)

OTC (over-the-counter drugs)

Source: DSM Group

Vital and Essential Drugs (VED) are a list of drugs approved by the Government of the

Russian Federation for the purpose of state regulation of drug prices. The share of VEDs

slightly exceeds 50% of the total volume of the drug market both in rubles and in physical

terms.

VEDs/non-VEDs sales ratio,

RUB

VEDs/non-VEDs sales ratio,

packages

51% 51% 50,8% 44,2%

49% 49% 48,7% 46,8%

49% 49% 49,2% 55,8%

51% 51% 51,3% 53,2%

2017 2018 2019 2020

2017 2018 2019 2020

VEDs

non-VEDs

VEDs

non-VEDs

Source: DSM Group

Source: DSM Group



13

In 2020, the share of original drugs increased compared to the previous year and amounted

to 43.7% in value and 15.9% in physical terms. This was due to an increase in funding for the

purchase of expensive medicines in the state segment.

Original/generic drugs sales ratio,

RUB

Original/generic drugs sales ratio,

packages

64% 61% 59,8% 56,3%

88% 86% 85,5% 84,1%

36% 39% 40,2% 43,7%

2017 2018 2019 2020

12% 14% 14,5% 15,9%

2017 2018 2019 2020

Original drugs

Generic drugs

Original drugs

Generic drugs

Source: DSM Group

Source: DSM Group

In the ATC 5 rating in 2020, the group [L] “Antineoplastic and Immunomodulating agents”,

which includes expensive drugs, has risen to the first place. Due to the increased funding in

the state segment, consumption of these drugs increased by 17%. The main channel for

financing the dispensing of antineoplastic drugs are pharmaceutical benefits programs

(federal and regional ones) – 35% and hospital purchases – 52%. At their own expense,

consumers usually only buy cheaper immunomodulators.

Group [A] “Alimentary tract and metabolism”, the leader in 2019, goes next in the rating: its

share is 15.0%. The drugs of this group are mainly sold in the pharmacy segment: 76% in

rubles is accounted for by the purchase of drugs at the expense of the population.

The largest growth – by 18% – was shown by group [J] “Antiinfectives for systemic use”. 53% is

purchased for the needs of hospitals, and the share of sales in the pharmacy segment was

43.7%. High dynamics of this group of drugs is explained by the Covid-19 pandemic.

ATC codes 1st level

Share in value

terms, %

Share in volume

terms, %

L: Antineoplastic and Immunomodulating Agents 16.01% 1.68%

A: Alimentary tract and metabolism 14.97% 15.09%

J: Antiinfectives for systemic use 13.90% 11.69%

5

Anatomical Therapeutic Chemical (АТС) Classification.

14



C: Cardiovascular system 10.12% 12.25%

N: Nervous system 8.44% 14.34%

R: Respiratory system 8.30% 12.86%

B: Blood and blood forming organs 7.76% 7.05%

M: Musculoskeletal system 6.10% 6.73%

G: Genitourinary system and sex hormones 4.52% 1.69%

D: Dermatologicals 4.20% 10.19%

S: Sensory organs 2.01% 2.21%

Non-ATC 1.39% 2.26%

V: Various 1.24% 0.80%

H: Systemic hormonal preparations, excluding

0.88% 0.80%

sex hormones

P: Antiparasitic products, insecticides

and repellents

0.17% 0.36%

Source: DSM Group



15

1.1.2 Commercial segment of the Russian pharmaceutical market

The results of the pharmaceutical market in 2020 were largely influenced by consumer

behavior in the context of the Covid-19 pandemic. With the emergence of news about the

methods of treating coronavirus infection, there was an increased demand for one or another

group of drugs. This led to an increase in sales, and at times a shortage, when manufacturers

were not ready to meet the demand in full.

According to DSM Group, at the end of 2020, the market growth in the commercial segment

in rubles was 11%, while in physical terms it remained in the negative zone – -2%. Thus, the

retail segment sold about 5.0 billion packages of drugs worth 1,128 billion rubles (in retail

prices).

Dynamics of the commercial drugs

market, RUB bln

Dynamics of the commercial drugs

market, mln packages

896 (+6%) (+5%) (+3%)

(+11%)

4 896

(+2%)

(+4%)

(-2%)

(-2%)

2016 2017 2018 2019 2020

Source: DSM Group

2016 2017 2018 2019 2020

Source: DSM Group

The consumption of drugs at the expense of the population's own funds remains one of the

main elements of the healthcare system drug supply: about 64% in monetary terms and

almost 85% in packages. Hence the high requirements for pharmacies who in this case act as

a sales channel. At the beginning of 2020, pharmacies were getting ready to sell labeled

medicines from July 1, 2020. But the spread of the new coronavirus infection created an

additional challenge: shortages of certain pharmacy products.

In 2020, there were no seasonal or other common trends inherent in the pharmacy market.

Antivirals and antibiotics were in greatest demand during the pandemic. Moreover, even in

summer, sales of these categories of drugs were significantly higher than in previous years.

The structure of drug consumption in 2020 was influenced by such macroeconomic factors as

the crisis caused by the pandemic, the lockdown, the decline of real disposable income (-3.5%

according to the Federal State Statistics Service), the change in household spending in favor

16



of mandatory payments and savings, the overall inflation rate (4.91%) and even higher one

for food products (6.7%).

The dynamics in the commercial segment of pharmaceuticals in 2020 was difficult to predict:

all previously established trends have changed. In March 2020, drug demand exploded and

the pharmaceutical market experienced one of the most significant sales gains in the past

few years. With the spreading coronavirus infection and the deteriorating economic

situation, consumers began to massively buy drugs, apprehending a rise in prices in the

context of a weakening ruble and a shortage of necessary drugs due to restrictive measures.

Subsequently, the sales dynamics were weak and even negative in some months. Only in

December, the market returned to the growth rates that were in January-February 2020, i.e.

before the events related to the pandemic. Since April, sales growth has been mainly driven

by anti-covid drugs. Their list varied, but due to the high demand for them, the market

showed positive dynamics in rubles (+10.6%) and decreased only in units – by 2.3%. In 2020,

5,002 million packages of drugs worth 1,128 billion rubles (in retail prices) were sold through

the pharmacy network.

Pharmacy sales of parapharmaceutical products, as it traditionally happens during crisis

periods, grew more slowly than sales of drugs: the volume of this segment grew by 6.7% and

amounted to 279 billion rubles. The growth was mainly noted due to dietary supplements (in

particular vitamins and immunity boosters), personal protective equipment (masks),

sanitizers, medical appliances. These types of goods are indirectly but related to preventing

the spread of Covid-19.



17

1.1.3 Drug reimbursement segment

According to the Russian legislation, under a number of drug reimbursement programs

(DRP), the costs of purchasing the necessary medicinal products for benefit-entitled social

categories are annually included in the draft budgets of various levels.

Since 2021, the Unified Register of Patients entitled to the provision of subsidized medicines

began to operate (Federal Law No. 206-FZ of July 13, 2020). In addition, at the end of 2020,

the Federal State Institution “Federal Center for Planning and Organization of Medicinal

Supply of Citizens” started working in Russia. This organization will determine the needs of

citizens in medicines, make joint purchases, and monitor regional activities.

One of the fundamental drug reimbursement programs is the Essential Drug Coverage

program on the provision of benefit-entitled citizens with necessary prescription drugs at the

expense of the federal budget in accordance with the standards of medical care.

From February 1, 2021, the standard of monthly financial costs per citizen receiving state

social assistance in the form of a social service for the provision of drugs, medical devices, as

well as specialized medical nutritional products for disabled children, was set at 886 rubles 40

kopecks.

From January 1, 2021, the Essential Drug Coverage list is no longer valid. From this year on,

social categories entitled to both federal and regional benefits shall be provided with free

drugs to the extent no less than that provided for by the vital and essential drugs (VED) list.

The VED list should be revised at least once a year.

According to the order of the Government of the Russian Federation No. 3073 of November

23, 2020, the VED list was expanded to 788 items in 2021. The list includes 25 new drugs. The

government has updated the rules for making the VED list: drugs that are used for the

treatment and prevention of dangerous diseases can be included in the VED list under an

accelerated procedure. This option is available in case of state of emergency and/or risk of

the spread of the abovementioned diseases, including COVID-19.

Two lists are still relevant: for high-cost ICD codes and the minimum range of drugs for

pharmacies.

The High-Cost ICD program has been operating since 2008 and initially included 7 ICD codes.

In 2019, the program was expanded to incorporate five more diseases, and from 2020 – 2

more ICD codes. Thus, today, “14 High-Cost ICD codes program” is a federal targeted state

program on the provision of expensive drugs to persons with hemophilia, cystic fibrosis,

malignant tumors of lymphoid, hematopoietic and related tissues, multiple sclerosis and

other diseases that cannot be completely cured.

The domiciliary drug reimbursement program for patients with cardiovascular diseases,

which has been in effect since 2020, has been extended until 2023 (Government Decree No.

2081 of December 11, 2020). In 2020, the amount of funds allocated under the program

amounted to RUB 10.15 billion; in 2021, over RUB 10 billion will also be allocated from the

federal budget.

18



According to DSM Group estimates, the scope of the regional DRP regulated by the

Government Decree No. 890 of July 30, 1994, is comparable to the federal one. The

constituent entities of the Russian Federation form their own lists of regional benefitentitled

social categories.

According to the DSM Group report, in 2020, 174 million packages of medicines worth RUB

233 billion were purchased for benefit-entitled categories of citizens, the decrease compared

to 2019 is 8% in rubles and 9% in packages.

DRP dynamics, RUB bln

DRP dynamics, mln packages

(+6%) (+6.7%) (+2.9%)

(+28.7%)

(-7.8%)

(-3.7%)

(+16.6%) (-6.7%)

(+21.6%)

(-9.3%)

2016 2017 2018 2019 2020

2016 2017 2018 2019 2020

Source: DSM Group

Source: DSM Group

In the DRP segment, one may see the growth of the regional pharmaceutical benefits’ share,

which accounts for more than half of the financing of the subsidized segment. By the end of

2020, the share of High-Cost ICD program also increased – to 28%, while the share of funds

for drugs under general ICD codes, which previously amounted to about 30%, decreased to

18% in 2020.

The ratio between localized and imported drugs in monetary terms in the DRP segment

remains in favor of the imported ones. In 2020, their share is 63% of the sales value, while

domestic drugs account for only 37%. This is due to the fact that under the DRP programs it is

usually the original expensive and most often imported drugs that are purchased.

The DRP segment is mainly represented by prescription drugs: at the end of 2020, their share

in value terms was 96.8% (+0.7% compared to 2019), in volume terms – 92.3% (+0.8%).



19

1.1.4 Segment of purchases of drugs for needs of healthcare

institutions

In 2021-2023, RUB 2.8 trillion rubles will be allocated for the implementation of the state

program “Development of healthcare”. Budget allocations in 2021 will amount to RUB 965.1

billion rubles, in 2022 – RUB 947.4 billion, in 2023 – RUB 911.5 billion.

According to the Russian federal budget for 2021 and for the planning period of 2022 and

2023, over RUB 3.3 trillion will be allocated for healthcare expenditures. 6 Budget allocations

for the Healthcare section in 2021 will amount to RUB 1,123.3 billion, in 2022 – RUB 1,112.8

billion, in 2023 – RUB 1,081.3 billion.

According to DSM Group, in 2020, the hospital segment of the pharmaceutical market is

experiencing the most significant increase in purchases over the past several years. For the

needs of healthcare institutions (HCI), 841.7 million packages of drugs worth RUB 400.7

billion in wholesale prices were purchased. The expenditure increased by 23.6% in value

compared to the previous year, while the volume of purchased packages decreased by 11.8%.

Hospital purchases dynamics,

рurchase volumes, RUB bln

Hospital purchases dynamics,

purchase volumes, mln packages

222

(+16.8%) (+3.4%)

(+20.8%)

(+23.6%)

883

(+17.5%) (-0.2%)

(-7.9%)

(-11.8%)

2016 2017 2018 2019 2020

Source: DSM Group

2016 2017 2018 2019 2020

Source: DSM Group

The trends observed in 2020 are driven by the Covid-19 pandemic, as well as the increase in

funding from federal programs such as oncology and prevention of cardiovascular diseases.

The change in the procurement structure in favor of drugs for the treatment of oncological

diseases led to the fact that the average weighted cost of a package of drugs purchased for

the needs of HCI in 2020 reached RUB 476, which is 40.1% higher than in 2019. At the same

6

Federal Law of December 08, 2020 No. 385-FZ.

20



time, the prices dynamics in the hospital segment is negative: in 2020, the price index for

medicines purchased via tenders is negative and amounts to -7%.

One of the trends in recent years has been an increase in the share of domestic medicines in

the hospital purchase segment, since, according to the legislation, they are given preference

in tendering both in terms of inclusion in the tender and in terms of price. Import

substitution developed in two directions: direct switching to domestic drugs and localization

of foreign manufacturers in Russia.

In 2020, with an increase in the purchase of “expensive” drugs, this trend was broken. At the

end of 2020, in the segment of hospital purchases, the share of imported drugs increased by

1.7% and amounted to 53.9%. In physical terms, localized drugs prevail: their share is 83.8%

(+0.6% compared to 2019).

The average weighted cost of a package of an imported drug at the end of 2020 amounted to

1,586 rubles (+50.7% compared to 2019). The average price of localized drugs is several times

lower: 262 rubles per package (+34% compared to 2019).



21

1.1.5 Dietary supplements segment

According to DSM Group, at the end of 2020, the volume of the commercial dietary

supplements market amounted to RUB 74.1 billion (+17.1% compared to 2019) or 321.8

million packages (-1.2%). A significant increase in sales was noted during the 1st quarter of

2020, then the jump in demand gave way to a drop in sales. In packs, the dietary supplements

market showed negative dynamics.

The reorientation of consumer demand in favor of taking vitamins and vitamin-containing

complexes is one of the main consequences of the Covid-19 pandemic’s impact on the dietary

supplements market.

Dietary supplements market

dynamics, RUB bln

Dietary supplements market

dynamics, mln packages

49.7 (+7.6%) (-0.8%)

(+19.1%)

(+17.1%)

343

(+3.9%)

(-9.4%)

(+1%)

(-1.2%)

2016 2017 2018 2019 2020

Source: DSM Group

2016 2017 2018 2019 2020

Source: DSM Group

22



1.1.6 Export of Russian pharmaceutical products

Despite the fact that the Russian pharmaceutical industry is currently underrepresented in

the international market, Russian enterprises are consistently increasing the volume of

export supplies (over the past 8 years, the decline was observed only in 2015). According to

the Russian Export Center, at the end of 2020, the export of pharmaceutical products from

the Russian Federation amounted to USD 1,058 million (an increase of 24.54% compared to

2019). Pharmaceutical products are ranked 27th in the ranking of Russian exported goods in

terms of export volume with a share of 0.31%. The main sales markets for Russian

pharmaceutical products are Kazakhstan, Ukraine, Belarus. The key exporting regions of

pharmaceutical products are Moscow, Moscow Region, Nizhny Novgorod Region, St.

Petersburg, and Rostov Region. 7

Dynamics of export volumes of pharmaceutical products in the

Russian Federation, USD mln

(+24.54%)

589 (+5.07%)

(-11.63%)

(+16.63%)

(15.12%)

(+8.23%)

(+7%)

2013 2014 2015 2016 2017 2018 2019 2020

Source: Analytical portal “Export of Regions” JSC “Russian Export Center”

According to the draft Strategy “Pharma-2030”, the export volume of medicines (excluding

other pharmaceutical products), in case of implementation of support measures, may reach

USD 3,800 million. The draft Strategy lists the main factors that can contribute to the

achievement of this ambitious goal, the risks that need to be taken into account and the

priorities for future support programs.

The end of the patent protection period for original biological products and the appearance

of biosimilars falls on 2019-2022. This trend is one of the key factors of the potential for

entering foreign markets with analogues of medicines, especially biotechnological ones.

7

Analytical portal “Export of Regions” JSC “Russian Export Center”: www.regionstat.exportcenter.ru.



23

The development of the innovative drugs segment in narrow therapeutic niches is another

promising direction for increasing domestic exports of pharmaceutical products. According to

the draft Pharma-2030 Strategy, Russian enterprises have created new molecules in such

highly demanded nosologies as HIV therapy (elsulfavirine), hepatitis C (narlaprevir), diabetes

mellitus (gozogliptin). Since 2009, 70 Russian medicines have been registered with

government support. A number of drugs are being registered in more than 60 countries

around the world, including the countries of Southeast Asia, Africa and Latin America.

The draft Strategy “Pharma-2030” emphasizes that in the process of developing support

programs high investment risks borne by companies seeking to enter foreign markets with

their products need to be taken into account. Any foreign markets are characterized by a

protectionist policy in relation to local companies, and regulatory requirements for drug

registration and inspections for compliance with national or international production quality

standards tend to become tougher. Therefore, in the draft the Strategy, it is proposed to

support projects that have local partners in target markets with a confirmed market share in

target segments or agreements providing for the sharing of risks or the transfer of part of

investments to local partners as well as risk insurance.

The draft Strategy also emphasizes that state support programs’ objectives should be to

increase the level of competence of local producers, to stimulate them to form intellectual

property objects and to protect these objects when entering foreign markets.

24



1.1.7 Manufacturing and export of pharmaceutical products in

St.Petersburg and Leningrad Region

Index of production of medicines and materials used for medical purposes in St. Petersburg

in 2018-2020 shows stable growth, while in Leningrad Region, after a significant decline in

2018, the pharmaceutical production index slightly increased in 2019 and then dropped again

at the end of 2020. 8

Indices of production of pharmaceutical products in St. Petersburg and Leningrad region, %

to the previous year

Activity

code

according

to

OKVED2

Name of the activity

according to OKVED2

21 Production of medicines and

materials used for medical

purposes

2018 2019 2020

SPb LR SPb LR SPb LR

110.4 89.8 106.3 100.9 113.9 98.1

Source: Office of the Federal State Statistics Service

for St. Petersburg and Leningrad Region (Petrostat)

Since 2016, exports of pharmaceutical products from St. Petersburg have shown significant

growth annually. At the end of 2020, the export volume of pharmaceutical products of

St. Petersburg amounted to USD 85.18 million (an increase by 30.07% compared to 2019 and

almost fourfold compared to 2015). St. Petersburg ranks fourth among the constituent

entities of the Russian Federation in this respect. At the same time, the share of

pharmaceutical products in the total export volume from St. Petersburg is quite small and

amounts to only 0.41%.

8

According to Department of the Federal State Statistics Service for St. Petersburg and Leningrad Region

(Petrostat)



25

Dynamics of pharmaceutical products export of St. Petersburg, USD mln

(+30.07%)

(+44.49%)

(+10.74%)

(+21.78%)

27,93 (-5.42%)

(-17.47%)

(+54.19%)

2013 2014 2015 2016 2017 2018 2019 2020

Source: Analytical portal "Export of Regions" JSC "Russian Export Center"

In 2020, the export volume of pharmaceutical products in Leningrad Region amounted to

USD 0.55 million (an increase of 242.03% compared to 2019 and a threefold increase

compared to 2015). The share of pharmaceutical products in the total export volume from

Leningrad Region is only 0.01%.

1,25

Dynamics of pharmaceutical products export of Leningrad region, USD

mln

(-64.19%)

(-59.19%) (+8.37%)

(+38.08%)

(-87.06%)

(+359.34%)

(+242.03%)

2013 2014 2015 2016 2017 2018 2019 2020

Source: Analytical portal "Export of Regions" JSC "Russian Export Center"

26



1.1.8 Government policy and support for the pharmaceutical industry

in Russia

The first strategy for the development of pharmaceutical industry in Russia for the period up

to 2020 9 (hereinafter referred to as the “Pharma-2020” Strategy) was approved in 2009.

In 2011, the federal target program (FTP) “Development of pharmaceutical and medical

industry” 10 appeared (terminated ahead of schedule by the Government Decree No. 1673

dated December 28, 2017), and in 2014, the state program of the Russian Federation

“Development of pharmaceutical and medical industry” 11 was adopted. The Ministry of

Science and Higher Education of the Russian Federation was appointed as the responsible

executor of the program measures. By Government Decree No. 359 dated March 29, 2019, the

implementation of the state program was extended until 2024.

Under the FTP, support was provided to domestic producers through R&D funding while

under the state program the key support mechanism is subsidies.

Under the state program, more than 50 new production sites were built, and even more were

modernized. The program made it possible to create competitive and more affordable

analogues of foreign drugs in such areas as oncology, immunology, virology and neurology.

As a result of the implementation of program activities aimed at research and development

of drugs, developments were carried out in the segments of anticancer, anti-infectious,

neuroprotective drugs, as well as drugs that affect the cardiovascular and central nervous

systems, hemostatics, anticoagulants etc.

In 2019, the Ministry of Industry and Trade of the Russian Federation announced changes to

the subsidy distribution scheme. According to the new rules, financial support for

manufacturers' costs is provided (i.e. an advance mechanism for providing subsidies), support

can be provided to projects from the stage of R&D and clinical trials to manufacturing

application. The grant recipients are determined through competitive procedures for each

critical technology. Proceeds from the sale of products created under the project and the

period of its implementation are set as indicators of the project implementation

effectiveness.

Another support mechanism, among other things for import substitution, is a special

investment contract (SPIC). From the beginning of 2020, a SPIC can be concluded on new

terms:

§ the minimum threshold for investment in the project is cancelled;

9

Order of the Ministry of Industry and Trade of the Russian Federation of October 23, 2009 No. 965 “On approval of

the Strategy for the development of the pharmaceutical industry of the Russian Federation for the period until 2020”

10

Decree of the Government of the Russian Federation of February 17, 2011 No. 91 “On the federal target program

“Development of the pharmaceutical and medical industry of the Russian Federation for the period up to 2020 and

further perspective”

11

Decree of the Government of the Russian Federation of April 15, 2014 No. 305 “On approval of the state program of

the Russian Federation "Development of the pharmaceutical and medical industry” for 2013-2020”

RUSSIAN-FINNISH LIFE SCIENCE INDUSTRY 27


§ the term of the SPIC has been extended to 15 years (for investments no more than

RUB 50 billion) and up to 20 years (for investments over RUB 50 billion);

§ the project must use a modern technology included in the list that is formed according

to the procedure approved by Government Decree No. 319 of March 21, 2020;

§ SPIC will be concluded with the simultaneous participation of the Russian Federation,

a constituent entity of the Russian Federation and a municipal entity;

§ applications for participation in the competition will be submitted in the remote

mode and considered on a competitive basis.

Since 2021, another mechanism for supporting the pharmaceutical and medical industry is

available. That is grants in the form of subsidies from the federal budget to budgetary

institutions for the implementation of projects on drugs and medical devices’ development. 12

Grants are awarded according to the results of a competition held by the Ministry of Industry

and Trade of Russia. The maximum size of a grant for the implementation of one project

cannot exceed RUB 260 million and make up more than 70 percent of the project

implementation costs. Grant applicants must submit a business plan for the project

containing a feasibility study and a scheduled plan for implementation.

State support for the pharmaceutical industry has shown good results over the past decade.

In particular, due to the implementation of the Pharma-2020 Strategy, the share of

domestically produced drugs increased from 20% (as of 2009) to 44%. There are achievements

in the segment of highly complex drugs: at present, the share of domestic drugs for the

treatment of oncological diseases in the Russian market exceeds 65% in physical terms. In

addition, during the implementation of the strategy, more than 50 new production sites were

built, dozens of enterprises were modernized, 130 drugs (including 9 innovative ones) were

introduced to the Russian market with state support. In the direction of implementing the

rules of good manufacturing practice, it is worth noting the creation of the institution of the

domestic inspectorate, as well as the establishment of a system of GMP inspections. The

Russian market has become more attractive and competitive: over the past ten years, more

than 100 international companies have localized the production of about 400 of their drugs.

Implementation of the Pharma-2020 Strategy

Indicator Actual value, 2020 Target value

Domestic Domestic + 2018 2020

localized

Share of domestic drugs in VEDs (SKU) 56% 63% 90% 90%

Share of domestic drugs in VEDs (volume, rubles) 36% 48% 90% 90%

Share of domestic drugs in total consumption in money 34% 44% 43% 50%

Share of domestically manufactured drugs by the

nomenclature of the list of strategically important

58% 65% 90% 90%

drugs

Source: DSM Group

12

Decree of the Government of the Russian Federation of December 21, 2020 No. 2187 “On approval of the Rules for

the provision in 2021 of grants in the form of subsidies from the federal budget to budgetary institutions for the

implementation of projects for the development of medicinal products and medical devices”

28 RUSSIAN-FINNISH LIFE SCIENCE INDUSTRY


In the summer of 2018, a draft order of the Russian Government “On Approval of the

Strategy for the Development of the Pharmaceutical Industry of the Russian Federation for

the Period up to 2030” (hereinafter referred to as the “Pharma-2030 Strategy”) was published

in the federal information system.

The Pharma-2030 strategy is focused on meeting the national goals and strategic objectives

of the Russian Federation. According to the Decree of the President No. 204 of May 7, 2018

“On national goals and strategic objectives of the development of the Russian Federation for

the period up to 2024”, the main goals and objectives in relation to the pharmaceutical

industry development are:

§ breakthrough scientific, technological and socially oriented development of the

Russian Federation and acceleration of the technological development of the Russian

Federation;

§ creation of a highly productive export-oriented sector in the basic sectors of economy,

developing on the basis of modern technologies and provided with highly qualified

personnel;

§ increasing the life expectancy of the population up to 78 years (by 2030 – up to 80

years).

According to the draft Strategy “Pharma-2030”, the main goal of the Russian state policy for

pharmaceutical industry development for the period up to 2030 is:

§ guaranteeing the security of the Russian Federation in the matter of drug supply to

the population and drug availability in all segments;

§ ensuring the advanced level of scientific, technical and technological development of

the pharmaceutical industry;

§ creation of export-oriented potential of the pharmaceutical industry;

§ availability of competencies in R&D, full-cycle production, introduction into clinical

practice and export of innovative medicines.

Expected results of the Strategy implementation are:

§ a significant increase in the volume and range of production of pharmaceutical

products to ensure the domestic market and the development of exports of finished

pharma products and pharmaceutical substances;

§ implementation of modern digital platforms in the industry and best regulatory

practices in the pharmaceutical industry;

§ meeting the needs of the healthcare system and the population in accordance with

the designated state priorities, as well as in the most expensive or voluminous niches

of the pharmaceutical market;

§ creation of a personnel training system to meet the needs of the pharmaceutical

industry, including the advanced educational and scientific infrastructure, among

other things via creating consortia with technology partners;

§ development of innovative, technical and technological infrastructure, increasing the

share of intangible assets of companies with the objective, among other things, of

increasing the export of pharmaceutical products.



The Pharma-2030 Strategy elaboration has been going on since 2018, with the deadlines for

its approval constantly being postponed. By the time of finalizing this report, the Strategy

has not been formally approved yet.

30



1.2 Key trends

1.2.1 Key development factors and events of the Russian

pharmaceutical market

According to DSM Group report “Russian pharmaceutical market 2020”, the pandemic of

coronavirus infection Covid-19 became the most important factor that had a multifaceted

impact on the Russian pharmaceutical market in 2020, affecting economic processes,

government regulation, and consumer demand.

First of all, the pandemic has accelerated the adoption in the Russian Federation of a number

of laws related to the pharmaceutical industry. On July 1, 2020, mandatory marking of

medicines was introduced in Russia. At the same time, the government, by Resolution

No. 955 of June 30, 2020, established a special procedure for the import and introduction of

unmarked drugs into circulation.

With the introduction of this system, market agents (pharmaceutical manufacturers,

distributors and retail chains) began to receive massive complaints about failures in the

information system for monitoring the movement of medicines along the distribution chain,

which led to the blocking of drug sales. Taking into account the epidemiological situation in

the country and the increased demand for drugs, the Ministry of Industry and Trade decided

to temporarily switch the drug labelling system to a “notification” mode of operation, and

the operator of the mandatory labelling Center for Research in Perspective Technologies

(CRPT) to cancel fees for drug labelling.

According to a CRPT statement at the end of 2020, the simplified mode of operation in the

drug labelling system would be valid indefinitely for pharmacies and medical organizations,

and until July 1, 2021 for other economic agents.

In order to create conditions for a smooth transition to strict traceability, the Ministry of

Industry and Trade of the Russian Federation also developed an initiative that was approved

by the Government at the end of January 2021: for drugs released into circulation before

February 1, 2021, the notification nature of the labeling (“rule of 15 minutes”) will be in

action until their expiration date.

As of February 2021, about 86 thousand participants were registered in the “Chestny ZNAK”

system, which roughly corresponds to the total number of pharmacies, medical institutions,

distributors and manufacturers. According to CRPT, in December 2020, the share of labeled

drugs in circulation was 32%. The number of registered codes in the system exceeded 6.6

billion packages, which is equivalent to the annual volume of drug consumption in physical

terms.

The Covid-19 pandemic also contributed to the introduction of the procedure for accelerated

registration of drugs and medical devices in case of emergency (Government Resolutions No.

441 and No. 430 of April 3, 2020). Thanks to this, a number of drugs for the treatment of

Covid-19, including Favipiravir and Levilimab, as well as more than 120 test systems for the



31

presence of viral RNA and antibodies to coronavirus infection, were brought to the market in

a short time. The special registration procedure was extended until January 1, 2022.

The task of uninterrupted drug supply was also facilitated by the fact that electronic

document flow began to operate in many procedures, the extension of GMP certificates was

introduced, and it became possible to inspect production in accordance with GMP rules in a

remote format.

One of the key issues in the pharmaceutical industry is the pricing method for drugs from the

list of vital and essential drugs (VED). The maximum registered prices established for a

number of drugs from the VED list make their production unprofitable. The depreciation of

the ruble makes the situation even worse. In this regard, many companies announce plans to

stop production of these drugs. In order to avoid the disappearance of inexpensive drugs

from the VED list from the market, the Federal Antimonopoly Service (FAS) prepared a draft

regulatory amendment that allows manufacturers to raise prices of VED-listed drugs if there

is a shortage in the market of a drug under one international nonproprietary name (INN),

pharmaceutical form and dosage.

An important government initiative was the authorization of online drug trade. For a long

time, the pharmaceutical community has successfully opposed the adoption of the bill, which

has been pending in the State Duma since 2017. However, the Covid-19 pandemic has

speeded up the decision. Decree of the President No. 187, which entered into force on March

17, 2020, provides for the opportunity to conduct retail sales of non-prescription drugs in the

remote mode. The sale of prescription drugs, narcotic and psychotropic drugs, as well as

alcohol-containing drugs (with a volume fraction of ethyl alcohol over 25%) via the Internet is

prohibited. In May 2020, the rules regulating online trading appeared (Government

Resolution No. 697 of May 16, 2020). The following requirements are imposed on sellers:

§ conducting pharmaceutical activities in (at least) 10 sales points in Russia;

§ availability of a website or mobile application;

§ availability of own courier service or a contract with a delivery service;

§ possession of a pharmaceutical license for more than 1 year (indicating drug retail

trade).

At the end of 2020, the Ministry of Health of the Russian Federation developed amendments

to the rules for online drug trade. The new version of the document provides for the

possibility of participation of aggregator sites (marketplaces) in distance selling, drug

delivery and the abolition of the requirement for 10 pharmacy outlets. A document aimed at

simplifying the admission of players to the market may be adopted at the beginning of 2021.

32



1.2.2 Problems and barriers of the Russian pharmaceutical market

The past decade has revealed a number of issues that are characteristic not only of the

development of the local pharmaceutical industry, but stemming from general trends in the

development of social systems and high-tech industries. This range of problems is outlined in

the draft Pharma-2030 Strategy:

1. The pharmaceutical market as a part of the global healthcare market depends on the

trends characteristic of the development of the entire system.

2. The main systemic problem is the lack of funding for social programs and, in particular,

healthcare, both in developed and developing countries.

3. Due to the lack of funding, all markets are trying to reduce or at least keep the healthcare

spending through various methods – price control, implementation of evidence-based

medicine mechanisms, replacement of original drugs with generic ones, strengthening of

regulatory barriers in registration or quality control of production and circulation of

medicines.

4. Many technological competencies are becoming more accessible in local markets, which

weakens the position of global pharmaceutical companies in the markets of developing

countries (in the light of expiration of patent protection for most of the expensive drugs in

recent years, this trend seems to be especially significant).

5. The development of medical science and personalized medicine makes it impossible to use

traditional systems of financing healthcare budgets, challenges the existing medical

standards and treatment regimens, proposes new models of informing the medical

community about diagnostic and therapeutic opportunities through the introduction of

telemedicine systems and systems to support medical decision-making.

6. Entering local markets with finished pharmaceutical forms becomes extremely difficult

due to the extremely high cost and regulatory risks when registering and inspecting the

quality of pharmaceutical production in the target market. Therefore, having competencies

in the matter of a full production cycle as well as singularity of products become even more

important to ensure the possibilities of export to foreign markets.

The main barriers for the Russian pharmaceutical industry include the following:

§ dependence of the local market on imported products;

§ pressure from the regulatory systems of countries producing pharmaceutical products

for export;

§ regulatory barriers in the registration of medicines and quality control of medicines

circulation;

§ lack of local technological competencies: the dependence of both the segment of

finished pharmaceutical forms production and the segment of pharmaceutical

substances synthesis of chemical and biotechnological production on the

manufacturers of laboratory, pilot and industrial equipment; strengthening of the

sanctions’ the role in the global system of access to innovative technology platforms;



33

§ training system in the field of modern chemical and biotechnological synthesis and

the interdisciplinary nature of modern technological platforms;

§ demand for the results of the introduction of new drugs and production technologies:

the lack of guaranteed incentives from the state for the development and

commercialization of new drugs and new types of pharmaceutical products against the

the common idea about better quality and consumer properties of imported products,

which has a significant impact on the behavior of the patient and medical community;

§ shortcomings of the state support measures system and insufficient efficiency of

public investments.

34



1.2.3 Forecasts for the development of the Russian pharmaceutical

market

According to DSM Group forecasts, in 2021 the market capacity will reach 2,171 billion rubles.

(+ 6% by 2020). Additional growth factors are not expected, the industry is waiting for the

recovery of the pre-pandemic consumption structure.

Dynamics of the Russian pharmaceutical market capacity, RUB bln

(+4.7%) (+3.7%)

1 523

401

226

(+9.5%)

(+7.7%) (+2.6%)

560

451 452

241 240 262

(+8.9%)

598

279

(+6.1%)

607

298

619

319

618

339

896 948 992 1 020

1 128 1 222 1 289 1 352

2016 2017 2018 2019 2020F 2021F 2022F 2023F

Commercial drug segment

Parapharmaceuticals

Public procurement

Source: DSM Group

According to the draft Strategy “Pharma-2030”, the forecasted volume of the market, taking

into account the financial and economic situation, may amount to RUB 5 trillion by 2030 in

consumer prices.

The draft Strategy “Pharma-2030”, developed in 2018, contains a forecast of the dynamics of

medicines export volumes under the “no change” and target scenarios until 2030. With the

implementation of the target scenario, the Russian export of medicines is expected to reach

USD 3,800 million by 2030.

It is noted that the implementation of the target scenario depends on the correct

understanding of macroeconomic trends and threats, creation of effective mechanisms to



35

counter external risks (for example, commodity dependence or pressure of high-cost new

treatment methods), as well as effective incentives to ensure not only long-term national

drug safety, but also creation of a powerful foundation helping domestic companies enter

foreign markets.

Medicines export forecast until 2030 ("no change" and target scenarios)

2 836,8

3 000 3 100

3 250

3 450

3 650

3 800

705,2

705,2

1 905,9

1 562,3

927,8 993,7

860,3 1 049,6 1 280,5

755,3 808,9 866,3

2 325,3

1 064,3 1 139,8 1 220,8 1 307,4 1 400,3 1 499,7

1 606,1

1 720,2

2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030

Export volume in the "no change' scenario, USD mln

Export volume in case of support measures implementation, USD mln

Source: Strategy “Pharma-2030” draft

Achievement of the target scenario indicators assumes an average annual growth rate of

Russian exports of 15-16% (in USD) over the next ten years. According to the National Rating

Agency, such dynamics is 2-3 times higher than both the historical and forecast growth rates

of the world pharmaceutical market. Thus, a multiple increase in the volume of Russian

exports of pharmaceutical products, as envisaged by the draft Pharma-2030 Strategy, seems

difficult to achieve.

36



1.3 Educational institutions

1.3.1 Saint Petersburg State Chemical Pharmaceutical University

Saint Petersburg State Chemical

Pharmaceutical University (SPCPU) – is the first

of its kind higher pharmaceutical educational

institution in Russia and a leader in the

training of specialists for the national

chemical and pharmaceutical industry.

In accordance with the Ministry of Education and Science of the Russian Federation rating,

SPCPU has the highest rating among pharmaceutical and medical universities in Russia. The

University trains pharmacists majoring in pharmacy, chemistry, commodity science.

Objects of professional activity of the pharmacists are medicines used for the treatment of

diseases, diagnostics, preventive measures, aftercare and hagiology. Graduates of the

university work not only at pharmaceutical enterprises and pharmaceutical warehouses but

also at control and analytical laboratories, forensic laboratories and other chemical

laboratories related to chemical synthesis, analysis, medicinal substances and finished

pharmaceutical products research.

Biotechnology department graduates ready to create and develop technologies for obtaining

new types of biopharmaceutical products obtained by microbiological synthesis, bio catalysis,

genetic and cell engineering or by nanobiotechnology.

Since 2014, SPCPU organizes the annual Russian-Finnish Symposium in partnership with

University of Turku and Åbo Akademi (Finland). Symposium is held alternately in St.

Petersburg or Turku and over the years has become a platform for dialogue between

representatives of both countries. The Symposium sections provide the opportunity for

students, scientists and experts in the pharmaceutical and biomedical fields to discuss their

scientific ideas, present results of joint researches, as well as outline key issues of the

industry.

The official presentation of the Russian-Finnish Life Sciences Center took part on October 19,

2017. This center is located on the territory of the university and was created in close

cooperation between SPCPU, University of Turku, Åbo Akademi, Turku Science Park and

Union of Medical and Pharmaceutical Projects. XXI Century.

Contact information

Professor Popov Str., 14

197376 St. Petersburg, Russia

+7 (812) 499 39 00

info@pharminnotech.com | https://spcpu.ru/



37

1.3.2 The Pavlov First Saint Petersburg State Medical University

Federal State Educational Institution of Higher

Education of the Russian Federation Ministry of

Health.

The Pavlov First Saint Petersburg State Medical

University is one of the leading Russian medical

and scientific centers. The university trains highly

qualified specialists in the following fields:

medical care, dentistry, clinical psychology, sports

medicine, pediatrics, adapted physical education and nursing care. Internship, residency

training, postgraduate education and doctoral programme are also provided. More than 5

thousand students, including foreign ones, study at the university every year.

The structure of the university includes 69 departments, including the Department of

Pharmacology as well as the Clinical Pharmacology and Evidence-Based Medicine

Departments, 56 scientific laboratories, 11 institutions (research institutions and centers).

University bases are located on the territories of university clinics and on the basis of 43 large

hospitals and clinics of St. Petersburg. Structure of the university includes Institute of

Pharmacology named after A.V. Waldman. Currently, the Institute includes

psychopharmacology, neuropharmacology, pharmacoepidemiology and biomedical statistics

departments, which consist of series of laboratories where efforts of teachers and

researchers are concentrated on successful solution of urgent problems of modern

pharmacology.

Research in the field of experimental and clinical pharmacology of neuropsychotropic drugs,

pharmacogenetics, pharmacoepidemiology and medical technology assessment are

conducted on the basis of the institution.

Scientific solution to a number of problems allowed developing new approaches to

pharmacotherapy of pain, to optimize assessment methodology of the narcogenic potential

for compounds of various classes and to identify new and promising analgesics.

The structure of the university also includes Department of Preclinical and clinical medicines

trials of medicines organization, medical technology and medical products.

The main areas of activity of the department are the following:

§ Expert evaluation of the topics for research work at the planning, execution and

reporting stages in order to comply with current regulations for organizing and

conducting preclinical and clinical research of biologically active substances, medical

products, technologies, materials, medical products and equipment;

§ Organization, methodological guidance and control over the conducting of preclinical

and clinical studies (hereinafter referred to as research) of biologically active

substances, medical products, technologies, materials, medical products and

equipment;

38



§ Collection, synthesis and analysis of information related to the researching;

§ Interaction with stakeholders of biologically active substances medical products,

technologies, materials, medical products and equipment circulation related to

research conducting in the University;

§ Interaction with Ethics Committee of the University at all stages of planning and

conducting research;

§ Coordination of activities of clinical, scientific, financial planning, international and

other departments of the University on issues related to the competence of the

Department. Coordination and execution of estimate-contractual, registration and

reporting documentation for research.

Contact information

Lva Tolstogo Str., 6-8


+7 (812) 338 71 61

info@1spbgmu.ru | https://www.1spbgmu.ru/ru/



39

1.3.3 North-Western State Medical University named

after I.I. Mechnikov

North-Western State Medical University named after I.I.

Mechnikov (NWSMU) was founded on October 12, 2011 as a

result of the merger of the two oldest educational medical

institutions in Russia - St. Petersburg Medical Academy of

Postgraduate Education and St. Petersburg State Medical

Academy named after I. I.I. Mechnikov. The founder of the

University is the Ministry of Health of the Russian

Federation.

The activity of the University is based on close cooperation

and coordination of educational, clinical and research

activities - this allows training competent specialists who have modern knowledge and are

able to apply it in practice.

Research work at the University is carried out in accordance with current trends in the

development of biomedical sciences, at the same time considerable attention is paid to

research in the field of health protection and sanitary and epidemiological well-being of the

population.

The structure of the university includes Department of pharmacology and pharmacy, central

research laboratory, science research institute of medical mycology named after P.N. Kashkin

and preclinical and clinical trials Department.

The priority areas of activity of the central research laboratory are the following:

§ Molecular genetic research – some of them are not carried out on the territory of St.

Petersburg and even in Russia;

§ Determination of substances by high performance liquid chromatography method –

using unique methods for St. Petersburg and Russia;

§ Immunological methods for determining biologically active agents;

§ Morphological research using the electron microscopy method;

§ Cultivation and studying cell cultures;

§ Range of manual biochemical methods.

The priority areas of activity of the preclinical and clinical trials Department are the

following:

§ Documents preparation for accreditation;

§ Negotiation of contracts on science and on clinical trials of medications and medical

products;

§ Preparation of documents for the Research Center for received medications, medical

equipment;

§ Accounting of funds received under contracts;

40



§ Documents preparation for receiving money by the staff of the Research Center under

a science agreement and for Clinical Trials of medications and medical products;

§ Documents preparation for reports on research contracts;

§ Document control and support of the Local Ethics Committee (documents on clinical

trials, initiative and scientific dissertation work).

Contact information

Kirochnaia Str., 41


+7 (812) 303 50 00

rectorat@szgmu.ru | https://szgmu.ru/rus/



41

1.3.4 Military Medical Academy named after S. M. Kirov

The first higher medical institution in Russia for the training of

class officers of the military department and members of the

medical service of the Armed Forces of the Russian Federation.

The pharmacy group is based at the Military Medical Supply and

Pharmacy Department. The department is one of seven

departments that were a part of the Military Medicine (Medico-

Surgery) Academy founded by a decree of Emperor Paul I on

December 18, 1798.

The main task of the scientific group is to improve the medical

supply of the Armed Forces of the Russian Federation. This process includes the following

activities:

§ Development and updating of guiding, normative and methodological documents

regulating the functioning of the medical supply system;

§ Development and improvement of modern equipment;

§ Development of modern technology for manufacturing and quality control of

medicines in the field;

§ Study of capabilities of the medical supply system of troops (forces) in different

conditions and situations.

The Scientific Research Center (SRC) is a structural subdivision of the Military Medical

Academy performing research activities and acting as the head research unit of the Academy

in the field of fundamental and applied problems research in military and medical spheres, as

well as problems of medical and professional military education.

The Federal State Budgetary Military Educational Institution of Higher Education "Military

Medical Academy named after S. M. Kirov" is accredited to conduct clinical trials of medicinal

products.

Clinical trials have been performed at the Academy since 1996. International multicenter

clinical trials and researches of medications from Russian pharmaceutical companies are

performed in different fields of medicine: neurology, endocrinology, gastroenterology,

rheumatology, cardiology, infectious diseases, dermatology, surgery, and anesthesiology.

Contact information

Akademika Lebedeva Str., 6


+7 (812) 292 32 63

vmeda@mil.ru | www.vmeda.org

42



1.3.5 Saint-Petersburg State Pediatric Medical University

Saint-Petersburg State Pediatric Medical University is the

oldest pediatric institution of higher education in the world.

Scientific research is traditionally one of the priority activities

in the university and includes all major areas of medicine.

According to scientometric indicators of RSCI, the university

ranks second among medical institutions of the Ministry of

Health of the Russian Federation and ranks 12th among all

scientific organizations in Russia.

At Children's Clinical Hospital of St. Petersburg State Pediatric

Medical University (the largest in Russia), students have the opportunity to get an internship

and be trained by leading specialists in the field of medicine since their first year of studies.

The clinical hospital is a federal medical institution with a huge scientific base and secular

traditions of the Leningrad school of pediatricians. The university is equipped with modern

diagnostic instruments; clinical and biochemical, bacteriological and virological laboratories

make it possible to conduct the whole range of research at the level of the latest world

standards.

St. Petersburg pediatricians share their scientific achievements and experience with their

colleagues at the annual all-Russian congress "Healthy Children are the Future of the

Country".

Contact information

Litovskaia Str., 2


+7 (812) 295 06 46

press@gpma.ru | www.gpmu.org



43

1.3.6 Saint-Petersburg State Institute of Technology

Saint-Petersburg State Institute of Technology is one of the oldest

universities in Russia that trains specialists in the field of chemistry,

chemical technology, biotechnology, nanotechnology, mechanics,

information technology, management and economics.

44

Today Saint-Petersburg State Institute of Technology presents new

cutting-edge research for modern branches of science and technology

in the following fields:

§ Rocket-and-space technology;

§ Information technology;

§ Materials science;

§ Functional materials;

§ Medicine;

§ Human life support and ecology.

The institute has Chemistry of substances and materials and Chemistry and biotechnology

faculties and also Engineering center (SPSIT). The structure of the university includes Cell

biotechnology and Molecular pharmacology research laboratories.

A scientific project carried out at the Cell biotechnology research laboratory is aimed at

studying the role of interleukin-36 proteins (IL-36) during inflammation. Proteins of the

interleukin-36 group belong to proinflammatory cytokines and have been studied only over

the past 10 years. Therefore, activation of these proteins and its mechanisms involved in

inflammation and not fully understood. The main tasks of studying are determination of

proteases responsible for IL-36 activation and identification of low molecular weight

inhibitors of these proteases.

Molecular pharmacology research laboratory was established in the framework of the subsidy

from the federal budget of the Russian Federation in order to provide state support of

scientific research conducted under the guidance of leading scientists in Russian educational

institutions of higher professional education within the framework of a grant from the

Government of the Russian Federation for scientific research in the direction of «Proteomics.

Molecular Pharmacology. Medical chemistry».

The aim of the project is to continue studies of the physiological function of p53 (p63, p73)

family proteins and to study t regulatory mechanisms of their stability due to small inhibitors

of the E3-specific ubiquitin ligase ITCH.

The Engineering Center of SPSIT was established as a base with modern analytical equipment

for scientific research and development carried out at the university and was aimed to ensure

development of the latest technologies in science-intensive areas of science and technology

and establish cooperation between the scientific team of the university and Russian and

foreign representatives of science, education and production.



Contact information

Moskovskii pr., 26


+7 (812) 494 93 39

office@technolog.edu.ru | http://technolog.edu.ru/



45

1.3.7 Peter the Great St. Petersburg Polytechnic University

Peter the Great St. Petersburg Polytechnic University (SPbPU) is a

federal state autonomous educational institution of higher

education.

In 2010, University received status of a national research

university which is recognition of role and capabilities of

University in both education and multidisciplinary research and

development. SPbPU consistently holds leading positions in the

ranking of technical universities in Russia.

The Institute of Biomedical Systems and Biotechnologies of SPbPU was established in 2017 as

the first center in Russia working in promising areas at the intersection of medicine,

engineering and physics.

The Institute of Biomedical Systems and Biotechnologies includes advanced departments and

groups of SPbPU with specialization in the field of life sciences, biotechnology and

biomedical engineering. The mission of the university is to train highly qualified specialists

in the field of biological engineering in the process of combining modern training programs,

scientific research and strategic partnership with leading scientific organizations and

industry.

Contact information

Politekhnicheskaia Str., 29


+7 (812) 775 05 30

office@spbstu.ru | www.spbstu.ru

46



1.3.8 Pharmaceutical Technical School of the St. Petersburg State

Chemical-Pharmaceutical University

The Pharmaceutical technical school is an independent

structural subdivision of the Federal State Educational

Institution of Higher Professional Education "Saint Petersburg

State Chemical Pharmaceutical University" of the Ministry of

Health of the Russian Federation.

Currently, the Pharmaceutical technical school is one of the

largest educational institutions for training pharmacists in the

Russian Federation. The number of students is about 800 people.

Training is conducted by the specialty 33.02.01 "Pharmacy" in accordance with the FSES SVE,

qualification - pharmacist (basic level of training). Training is provided on the basis of

secondary general education and on the basis of medical education. The technical school has

30 classrooms and has own compounding pharmacy, chemical laboratories and other rooms

and laboratories to ensure the implementation of training programs. The following

disciplines are taught in the technical school: the humanities, general and vocational

disciplines, special disciplines such as pharmacology, the organization of the pharmacy

activities, dispensing of medicinal products, pharmacognosy, technology of medicines and

pharmaceutical chemistry. Students consolidate their theoretical knowledge during

internships and pre-graduation practice, which takes place at the bases of the best

pharmacies of different forms of ownership in St. Petersburg and the Leningrad region.

Graduates of the college are in high demand on the Russian pharmaceutical market. Each

year the Technical school graduates about 150 specialists.

Contact information

Tatarsii lane, 12-14


+7 (812) 232 49 48

spbfarmt@spbfarmt.ru | http://spbfarmt.pharminnotech.com/



47

1.3.9 Saint-Petersburg Medico-Social Institute

market.

Educational institution of higher education "Saint-Petersburg

Medico-Social Institute" is the only non-state higher educational

institution of medical orientation in St. Petersburg and the North-

West region. Mission of the university is to improve public health

through quality training of students based on modern achievements

of medical science in the dynamically changing needs of the labor

The Institute has a material and technical base providing opportunities for all kinds of

laboratory, disciplinary and interdisciplinary training, practical and research work in

accordance with educational plan. The Institute trains doctors in the specialties of medicine

and dentistry and provides additional education in health care and social rehabilitation.

Contact information

Kondratievskii pr., 72 lit. A


+7 (812) 448 39 63

info@medinstitut.org | www.medinstitut.org

48



1.4 Scientific institutions

1.4.1 All-Russian Research Institute of Food Additives

All-Russian Research Institute of Food Additives is a branch of the Federal

Scientific Center of Food Systems named after V. M. Gorbatyi of the Russian

Academy of Sciences.

The areas of activity of the All-Russian Research Institute of Food Additives are:

§ Fundamental, exploratory and applied scientific research of food additives, flavorings

and technological auxiliaries;

§ Microbiological and chemical synthesis of food additives and study of metabolic

pathways in biotechnological processes;

§ Breeding work with microorganisms and strains-producers of food micro-ingredients,

implementation of molecular-genetic procedures with producers of food additives in

order to intensify the biosynthetic processes;

§ Creation of new technologies for food additives and other micro-ingredients;

§ Development of technologies and ways of utilization of secondary raw materials;

§ Study of mechanisms and conditions to improve the quality and storability of

products, including the use of nanostructures in food matrices;

§ Development of safe product formulations based on promising natural components;

§ Development of methodology and techniques for identifying and controlling the

content of food micro-ingredients in various food products;

§ Development of draft normative, technical and methodical documentation;

§ Patent searching and registration of applications for intellectual property objects;

§ Organization of scientific conferences, seminars, exhibitions, competitions, etc;

§ Development of initial data for design of food additives production facilities, business

plans of established enterprises, project expertise;

§ Foreign economic activities.

Contact information

Liteinyi pr., 55


+7(812) 273 75 24

info@vniipd.ru | www.vniipd.ru



49

1.4.2 Almazov National Medical Research Centre

Almazov National Medical Research Centre of the Russian Ministry

of Health is the largest healthcare institution of this type in the

North-West Federal District.

Structure of the center includes the main clinical complex,

perinatal center, treatment and rehabilitation complex, treatment

and rehabilitation complex for children and Russian Research

Neurosurgical Institute named after Professor A.L. Polenov.

During reconstruction of buildings, the clinic received high-tech

equipment from world manufacturers, including a sterling hybrid operating room and a Da

Vinci robotic system.

The Institute of Medical Education consists of 14 departments and provides residency

training, postgraduate education and doctoral programmes. In 2018, the first recruitment of

75 students in the General Medicine Department took place.

Since October 2019, the Center has a status of “World Health Organization collaborating

institution”.

The structure of the center includes the National institute of education of clinical research

and evidence-based medicine, established in 2006 in order to organize, coordinate and

implement methodological guidance and control of research. The key tasks of the

department are the following:

§ Development of a regulatory framework for research within the Center;

§ Organization of staff training in accordance with suitable clinical practice (GCP);

§ Interaction with regulatory structures and contracting firms;

§ Interaction with the Ethics Committee;

§ Development of the preclinical and clinical trials system at the Center.

In 2010, the Clinical trials department was transformed into a separate research unit.

Contact information

Akkuratova Str., 2


+7 (812) 702 37 06

pr@almazovcentre.ru | www.almazovcentre.ru

50



1.4.3 Group of scientific research institutes

The group of research institutes includes such organizations as SPA

“House of Pharmacy”, the St. Petersburg Institute of Pharmacy, and

the Institute for Preclinical Research.

The group of research institutes is the largest research center in Russia, combining a worldclass

nursery and vivarium, modern laboratories with high-tech equipment and an

educational center. The group employs over 150 people: scientists, experts, veterinarians.

Potential of the group allows to provide different stages of medication life cycle

development from idea and molecule search to preparation of registration dossier in

accordance with EAEC and OECD requirements. The own nursery on the group basis (10 types

of animal species) allows to conduct preclinical studies in accordance with all international

standards in a short time.

Contact information

Zavodskaia Str., 3-245

Kuzmolovskii urban settlement, Vsevolozhskii district

188663 Leningrad region, Russia

+7(812) 603 74 28

info@doclinika.ru | www.doclinika.ru



51

1.4.4 Institute of Cytology RAS

Institute of Cytology is the head institution of

the Russian Academy of Sciences for the study

of cell biology and cell life activity on a wide

comparative material from unicellular

organisms to mammals, using the whole

arsenal of morphological, physiological,

biochemical and physicochemical methods. In 1959, "Cytology" journal and the Scientific

Council of the USSR on Cytology Problems (currently Scientific Council on Cell Biology and

Immunology of the Russian Academy of Sciences) were established at the base of the

Institute. These organizations were supposed to contribute to the university activities.

Later, on the basis of the Institute were established: the Society of Cell Biology at the Russian

Academy of Sciences, the Society of Protozoologists at the Russian Academy of Sciences (SPR),

the Association of Specialists in Cell Culture (ASCC), the Russian Collection of Cell Culture

(RCCC), the basic Department of Physical and Chemical Cell Biology at the Faculty of Medical

Physics and Bioengineering of the Saint Petersburg State Technical University and

“Protistology” international journal.

At present, the Institute includes 2 departments, the vertebrate cell culture collection, 19

laboratories, 17 groups, and auxiliary units. The Institute has more than 300 employees,

including 1 academician, 1 corresponding member of RAS, 41 doctors and 143 candidates of

sciences.

Contact information

Tikhoretskii pr., 4


+7 (812) 297 18 29

cellbio@incras.ru | www.incras.ru

52



1.4.5 Institute of macromolecular compounds RAS

The Institute of macromolecular compounds Russian

academy of science conducts fundamental and applied

research and development in the field of polymer,

organic, physical, bioorganic chemistry, experimental

and theoretical physics of high-molecular compounds.

The main fields of activity of the institute are the following:

§ Chemistry of high-molecular compounds, studying patterns of formation, chemical

and structural transformations of high-molecular compounds;

§ Development of principles for creation of functional polymeric materials, including

high-strength and high-temperature resistant structural materials and

nanocomposites;

§ Theoretical and experimental physics and mechanics of polymers, computer

simulation of complex macromolecular systems;

§ Development of scientific principles for the synthesis of a new generation of bioactive

polymers;

§ Targeted modification of medical and biologically active substances by natural and

synthetic high-molecular compounds for their application in medicine,

bioengineering, and biotechnology.

Contact information

Bolshoi Prospect V.O., 31


+7 (812) 323 74 07

imc@hq.macro.ru | www.macro.ru



53

1.4.6 Kashkin Research Institute of Medical Mycology

Kashkin Research Institute of Medical Mycology is the only

institution in Russia where problems of mycology (the

science of microscopic fungi) are solved by a large team of

researchers, physicians, and teachers. The institute is the

Scientific and Methodological Mycology Center of the

Russian Ministry of Health and Social Development with

status of the first reference institution in Russia for

medical mycology and a reference center for verification

of mycological research results of the Russian Ministry of

Health.

This clinic is the only medical institution in Russia and all

CIS countries, where patients with various mycoses from different cities of Russia, as well as

from other countries are treated in accordance with international recommendations. In

addition to patients with mycoses, clinic examines and treats patients with various

immunodeficiency disorders and allergic diseases, which are often caused by microscopic

fungi.

New methods of molecular genetic analysis for early diagnosis of invasive mycoses,

identification and typing of fungal pathogens, as well as scientific research in the field of

medical mycology are being implemented on the basis of the molecular genetic laboratory.

Contact information

Santiago-de-Kuba 1/28


+7 (812) 303 51 41

mycobiota@szgmu.ru | https://mycology.szgmu.ru/

54



1.4.7 Regional Engineering Centre for microreactor synthesis of

active pharmaceutical ingredients

Technopark.

In July 2016, the interdisciplinary Regional

Engineering Centre For Microreactor Synthesis of

Active Pharmaceutical Ingredients (REC API) was

established at the site of Saint Petersburg

The REC API develops unique technologies for the synthesis of pharmaceutical substances

which are fundamentally different from traditional ones.

The Centre is equipped with the only in Russia laboratory and pilot microreactor synthesis

units for implementation and development of continuous flow reaction technologies.

The scientific team of REC API has exceptional competences in this area and solves complex

tasks from development to transfer of technology to production.

Contact information

Aptekarskii lane, 2


+7 (812) 670 10 85 (148)

ec-api@ingria-park.ru | www.ec-api.ru



55

1.4.8 Research Institute of Hygiene, Occupational Pathology and

Human Ecology

The main activity of the Federal State Unitary

Enterprise "Research Institute of Hygiene,

Occupational Pathology and Human Ecology"

of the Federal Medical and Biological Agency

of Russia includes studying and developing

measures for scientific support of medical and hygienic support of operations with hazardous

chemical technologies, new chemicals and other types of economic activity.

Leading directions of research works of the institute are:

§ Development of medical and hygienic bases for labor and environmental medicine,

drafts of regulatory, methodological and other documentation to ensure sanitary and

epidemiological safety;

§ Complex toxicological, medical and hygienic, ecological and chemical analytical

studies;

§ Medical, ecological and hygienic and other types of expertise;

§ Establishment of hygienic standards for chemical substances, including

nanomaterials, in various industrial and environmental conditions, food products and

biological medias;

§ Searching and development of methods for determining biochemical markers in

experiments on animals and humans who have been in contact to poisonous

substances.

Contact information

Kapitolovo st., building №93

Kuzmolovskii urban settlement


+7 (812) 449 61 77

niigpech@rihophe.ru | www.rihophe.ru

56



1.4.9 Saint-Petersburg Scientific Research Institute of Vaccines and

Serums

The Saint-Petersburg Scientific Research Institute

of Vaccines and Serums of the FMBA of Russia is a

recognized leader in the development and

production of vaccines for influenza prevention in

the Russian Federation.

Mission of the institute is to develop and produce

safe, effective and competitive means of

prevention and treatment of infectious diseases for domestic and global markets.

Institute collaborates with leading vaccine developers through international organizations:

§ DCVMN (Developing Countries Vaccine Manufacturers Network);

§ IFPMA (International Federation of Pharmaceutical Manufacturers & Associations);

§ IVC (Association of Influenza Vaccine Suppliers).

The Scientific Research Institute is one of the founding companies of pharmaceutical and

medical industry of St. Petersburg and is one of the organizations that have a significant

impact on the industry and trade of the Russian Federation.

Institute experts are actively involved in the implementation of a number of approaches to

combat current infections at the WHO level and are members of WHO working groups in the

following areas: seroepidemiology, animal models, vaccine target product profile, clinical

study protocol (core protocol) and comparative characterization of vaccines candidates.

The research institute is working in the following areas:

§ Optimization of influenza vaccine production technology at all stages of the

technological process;

§ Development of effective technologies for producing influenza vaccines, including

pandemic vaccines;

§ Selection of influenza virus reassortants for the production season and the selection

of conditions for their cultivation;

§ Operational support and analysis of the results of the influenza vaccine production

process;

§ Creation of a national test system for the quantitative determination of

hemagglutinin;

§ Creation of alternative methods of quality control of influenza vaccines.

Contact information

Svobody Str., 52, Krasnoe Selo


+7 (812) 660 06 10

reception@spbniivs.ru | www.spbniivs.ru



57

1.4.10 Saint-Petersburg Pasteur Institute

Currently, the St. Petersburg Pasteur Institute is conducting fundamental

and applied research in the field of epidemiology, microbiology and

biotechnology in order to ensure the sanitary and epidemiological wellbeing

of the population of the Russian Federation. The structure of the

Institute consists of fifteen research laboratories and four departments, on

the basis of which two WHO subnational laboratories operate for the

diagnosis of poliomyelitis and for the diagnosis of measles / rubella;

reference centers for monitoring typhoid fever and for yersiniosis; Scientific

and Methodological Center for Epidemiological Surveillance of Viral Hepatitis; regional

centers for epidemiological surveillance of poliomyelitis, measles / rubella, salmonellosis,

rickettsiosis, North-West District Center for the Prevention and Control of AIDS. The Institute

as a whole performs the functions of a scientific and methodological center for monitoring

infectious disease pathogens in the North-West Federal District.

In addition to scientific laboratories, the Institute includes the Testing Laboratory Center,

the Medical Center, the Publishing House, and the Pilot-Industrial Production, which

produces a wide range of diagnostic products and selective nutrient media for the cultivation

of microorganisms.

The Institute carries out close and constant interaction with sanitary-epidemiological

services, health authorities, the service for supervision of consumer rights protection and

human welfare.

Contact information

Mira Str., 14


+7 (812) 233 17 03

pasteur@pasteurorg.ru | www.pasteurorg.ru

58



1.4.11 Scientific and Clinical Center of Toxicology named after

academician S.N. Golikov

The Institute of Toxicology is a medical scientific institution conducting

fundamental researches in the field of toxicology, pharmaceutical

chemistry and pharmacology, as well as the creation on this basis of new

tools and methods of prevention and treatment of poisoning.

Currently, the main task of the Institute is to obtain new scientific

knowledge in the field of natural sciences and use it in the interests of

public health, ensuring the defense and national security, as well as environmental

protection.

Toxicology of xenobiotics remains one of the main areas of scientific research at the

Institute. This traditional area of research is related to the study of the mechanisms of toxic

action, the identification of molecular-receptor and physiological targets of poisons and the

assessment of the severity of intoxication manifestations and toxicometric parameters of a

wide range of chemical compounds.

Another important direction of research is development and implementation of special

means of medical protection and pharmacotherapy of poisoning. The solution of this

problem involves two basic approaches. The first one is experimental therapy of intoxication

using available pharmacological agents, including the development of schemes and

evaluation of the therapy efficacy, as well as the creation of combined dosage forms. The

second approach involves creation of original antidotes and therapeutics for intoxication,

which includes the entire process from the idea of chemical synthesis to the industrial release

of the drug.

One of the few centers in Russia for the creation and practical implementation of effective

medical protectors (antidotes and pathogenetic therapy means) against poisonings with

highly toxic chemicals based on the study of patterns of chemical-biological interaction and

mechanisms of toxic action.

Along with pharmacotherapy of poisoning, this sphere allows to develop and implement

medicines used in clinics for various pathological conditions.

The Institute of Toxicology is one of the organizations performing preclinical studies of

medicines. Leading specialists have state and international certificates (Helm global group

company Ireland and Bioindustry initiative program of state department USA) confirming

their qualification in the field of preclinical studies according to GLP system.

The Preclinical Research Center of Toxicology Institute of Federal biomedical agency of

Russia complies with the principles of appropriate laboratory practice of OECD (GLP OECD).

Two Dissertation Councils (DS 208.030.01 since 2010, DS 208.006.01 since 2011) are currently

working at the Institute. Councils have the right to consider doctoral and candidate

dissertations in the following specialties: 14.03.04 - toxicology (medical and biological

sciences); 14.03.06 - pharmacology, clinical pharmacology (biological sciences).



Contact information

Bekhtereva Str., 1


+7 (812) 365 06 80

institute@toxicology.ru | www.toxicology.ru

60



1.4.12 Smorodintsev Research Institute of Influenza

Currently, the Smorodintsev Research Institute of Influenza

Ministry of Health of the Russian Federation is one of the

leading research centers for solving key issues of virology,

epidemiology, clinic and pathogenesis of viral infections,

development of highly sensitive diagnostic medicines and

effective means of protecting the population from influenza

and other dangerous viral infections. The Federal Influenza

and ARI Center and the WHO National Influenza Center

successfully operate on the basis of the Institute as an integral

part of the system of global surveillance of infections. The

most important part of the scientific activity is the study of molecular-genetic and

phylogenetic peculiarities of actual viruses. Research institute develops ways to predict

directions of variability of influenza viruses and other viral agents.

Research institute conducts studies in order to identify genetic determinants of

pathogenicity of existing and emerging viruses, to predict the evolution of influenza viruses.

The Institute has created a hardware and methodological infrastructure that allows to

conduct a wide range of biochip studies, as well as to develop its own diagnostic methods

based on protein and DNA biochips.

On the basis of research institute methods of immune-enzyme analysis are being improved,

new highly sensitive diagnostic test systems for influenza and other ARD viruses based on

monoclonal antibodies and rapid diagnostic preparations are being developed and produced.

The Institute is developing and testing new influenza vaccines and has made progress in their

design and production technologies. The institute pays special attention to vaccine safety.

Further research on recombinant influenza vaccine based on hybrid protein M2eHBc, a live

attenuated replication-deficient Fluvak influenza vaccine is promising and feasible.

Employees of the Institute conduct research and directed synthesis of antiviral medications

and develop new dosage forms.

New scientific directions in medications development include the following:

§ chemotherapeutic agents (Russian innovative projects);

§ antiviral and antibacterial medications based on peptides and recombinant proteins.

The research institute of influenza has a specialized clinic. The clinic provides consultative

and diagnostic assistance to patients, treats influenza and other acute respiratory infections,

herpes infections, chronic hepatitis, and conducts clinical trials of new therapeutic and

prophylactic medicines.



61

The Institute has Influenza and ARD virus museum based at the laboratory of evolutionary

variability of influenza viruses, which presents to interested organizations human and animal

influenza virus strains, adeno-, corona-, herpes-, PC- and other viruses from the museum

collection.

The Institute conducts international scientific and technical cooperation within the

framework of partnership projects and agreements with scientific institutes, institutions,

National and WHO Collaborating Centers on Influenza in the field of influenza surveillance

system, molecular virology, genetic engineering, improvement of influenza diagnostics,

design and production of new influenza vaccines and drugs

Contact information

Prof. Popova Str., 15/17


+7 (812) 499 15 90 (ext. 1661)

office@influenza.spb.ru | www.influenza.spb.ru

62



1.4.13 State Research Institute of Highly Pure Biopreparations

The Federal State Unitary Enterprise "The State Research

Institute of Highly Pure Biopreparations" of the Federal

Medical and Biological Agency of Russia was founded in

Leningrad in 1974 and has been successfully engaged in

biotechnology developments for over 45 years.

The mission of the institute is to ensure scientific

substantiation of biotechnological approaches to creation of

new generation medicinal products.

The institute specializes in the development, production and implementation of innovative

domestic medicinal products.

The scientific activity of the Institute is aimed at designing new medicines based on

recombinant and natural proteins; at development of technologies for their production,

creation of medicinal products and diagnostic systems based on synthetic peptides and

monoclonal antibodies; development of new effective pharmaceutical forms and medical

devices of prolonged and directed action, research of molecular and biological basis of AIDS

pathogenesis and development of a vaccine against HIV infection.

Contact information

Pudozhskaia Str., 7


+7(812) 499 16 50

secretary@hpb.spb.ru | www.hpb.spb.ru



63

1.4.14 V. M. Gorbatov Federal Research Center for Food Systems

During 25 years, the Research test center of the Federal State

Budgetary Institution "V. M. Gorbatov Federal Research

Center for Food Systems" of the Russian Academy of Sciences

(RAS) has been implementing works to confirm the quality and

safety of food products.

The strategic goal of the Research Center is to achieve and

maintain its leading position in food testing. The main

objective of the R&D Center team is to improve all processes of

the quality management system and dissemination of

information about scientific and research work to create additional opportunities in the

methodological implementation and promotion of developed research results for a wider

audience.

Research and Development Center helps to solve tasks successfully and cope with problems

promptly and conducts independent and high-quality tests and examinations, including

those for the Federal Executive Authorities; participates in the settlement of disputes.

The Laboratory of Research center was established in order to achieve the goals of the

national project «International Cooperation and Export», specifically the goals to reduce

financial and time costs of exporters in conformity assessment of exported goods by

developing and modernizing the Russian laboratory base, which include:

§ Reduction of exporter's costs for testing of products for compliance with requirements

of priority export countries;

§ Reduction of exporter's costs for logistics services for delivery of prototypes and

testing on the requirements of priority export countries;

§ Reduction of response time for product compliance with requirements of target

market.

Experimental clinic-laboratory is a research laboratory established in 2010, which activity

related to fundamental and applied issues in the field of experimental biology and medicine.

The laboratory conducts research work aimed at studying biologically active substances of

animal and plant origin, creation of specialized and functional foods, medicines and

ingredients for human and veterinary medicine on their basis. The key task of the unit is to

revive the tradition of developing unique medications based on animal raw materials. The

idea of creating medicines based on natural raw materials arised from studying the finest

biochemical mechanisms in a living organism, selecting biological regulators that affect

specific links in the metabolism, to determining their effectiveness and bioequivalence in

vivo.

The laboratory uses the latest achievements in biotechnology, biochemistry, physiology,

lanimalogy and nutritiology.

64



Contact information

Talalikhina Str., 26

109316 Moscow, Russia

+7 (495) 676 95 11

pr@vniimp.ru | www.vniimp.ru



65

1.5 Events

1.5.1 Events calendar

Date Event Venue | Format Details

International events

22.02.2021 BIO Asia Digital www.2021.bioasia.in

20-23.04.2021 Nordic Life Science Days Digital www.nlsdays.com

10-11.06.2021

14-18.06.2021

BIO International Convention

Digital

Digital

www.bio.org/events/bio-digital

15-16.09.2021 HealthBIO Hybrid

Turku (Finland)

www.turkubusinessregion.com

22-25.09.2021 EXPOPHARM 2021 Düsseldorf (Germany) www.expopharm.eu

13-15.10.2021 BioJapan Tokyo (Japan) www.ics-expo.jp

25–27.10.2021 BIO-Europe Digital | Hybrid

Stockholm (Sweden)

www.informaconnect.com

9-11.11.2021 CPhI Worldwide Milan (Italy) www.cphi.com

15-18.11.2021 MEDICA Düsseldorf (Germany) www.medica-tradefair.com

08-10.12.2021 INTERPEHX JAPAN Tokyo (Japan) www.interphex.jp

National events

2-4.03.2021 APTEKA Moscow (Russia) www.aptekaexpo.ru

14-17.04.2021 IPhEB Russia St. Petersburg

(Russia)

www.gotoipheb.com

10.2021 BIOTechMed Gelendzhik (Russia) www.biotechmedconf.ru

66



1.5.2 International events

1.5.2.1 BIO Asia

The BIO Asia International Conference (BIO Asia) is one

of the world's leading bioindustry events.

BioAsia seeks to enhance, enrich and encourage newer

innovations, path-breaking discoveries and effective

solutions in the industry by offering a vibrant global

platform for convergence of the key stakeholders - Biotech & Biopharma Companies, research

institutions, investors, service providers, policy makers, regulators and analysts.

With an objective of optimizing the immense business potential of biotech, BioAsia enables

an effective environment for fostering collaborations, joint ventures, M&As that has

increasingly become an integral part of industry growth agenda. BioAsia also provides a

dynamic platform for companies to exhibit, launch and showcase their unique strengths,

products and services. As an entity committed to the promise of Biotechnology, BioAsia

encourages knowledge and experience sharing amongst industry players, academia, young

research scientists to promote innovations and initiatives through appropriate awards and

recognitions. In addition, by creating a dynamic coterie of experience sharing from global

industry thought leaders and through panel discussions, BioAsia is committed to play a key

role in advocating issues to the policy makers and in chartering the road-map ahead.

Details

Date: February 22, 2021

Venue:

WWW:

Hyderabad (India)

www.2021.bioasia.in



67

1.5.2.2 Nordic Life Science Days

Nordic Life Science Days is the largest

Nordic partnering conference dedicated to

the life science industry. Since its inception

in 2013, the event has nurtured a

community of people from the world of life

science, and created a unique place to do business. Most attendees express their delight in

the informal atmosphere, combined with an organizational approach, meetings with highly

relevant people. Return visitors come back because they feel they belong to growing

community.

Nordic Life Science Days is the fastest growing life science event in the Nordic region,

attracting a highly relevant audience. Additionally, the high quality of topics and presenters

provide insight into the most recent trends in science and business. NLS Days attracts leading

decision makers from biotech, pharma and medtech as well as finance, research, policy and

regulatory authorities.

Details

Date: April 20-23, 2021

Format:

WWW:

Digital

www.nlsdays.com

68



1.5.2.3 BIO International Convention Digital

BIO is the world's largest trade association representing

biotechnology companies, academic and research institutions, state

biotechnology centers and related organizations across the United

States and in more than 30 other nations.

BIO members are involved in the research and development of

innovative healthcare, agricultural, industrial and environmental

biotechnology products. BIO also produces the BIO International

Convention, the world’s largest gathering of the biotechnology industry, along with industryleading

investor and partnering meetings held around the world.

Corporate members range from entrepreneurial companies developing a first product to

Fortune 500 multinationals. This company also represents state and regional biotech

associations, service providers to the industry, and academic centers. Its members help foster

a healthy economy by creating good-paying, biotechnology jobs. BIO also hosts the largest

cost-savings program in the life sciences industry, BIO Business Solutions, which saved $430

million in aggregate for 3,700+ companies last year.

BIO also works towards enriching the industry with networking, partnering and education

opportunities. The company organizes the BIO International Convention, the global event for

biotechnology, along with many other industry-leading investor and partnering events held

around the world. Arguably the industry’s leading partnering software, BIO One-on-One

Partnering facilitates 50,000 face-to-face meetings each year among investors, biotechs,

pharmaceutical companies, academic institutions and non-profits at live events.

Details

Date: June 10-11 & 14-18, 2021

Format:

WWW:

Digital

www.bio.org/events/bio-digital



69

1.5.2.4 HealthBIO

The HealthBIO event organized since 2007 has become the

biggest annual Finnish health-biotech company meeting.

HealthBIO Partnering Day in Turku brings together Finnish life

science companies, big pharma and diagnostics companies as well

as selected European investors.

The event offers the opportunity to meet life science SMEs and

rising stars at one-to-one meetings. HealthBIO is the largest

annual Finnish biotech company event, gathering 200-250 experts

from drug development, diagnostics and med-tech field.

Due to coronavirus situation, HealthBIO event was exceptionally arranged as an one-day

hybrid event. Number of on-site attendees was limited to 25 persons, and more than 100

followed presentations online.

Details

Date: September 15-16, 2021

Venue:

Format:

WWW:

Turku Science Park Ltd - Turku (Finland)

Hybrid

www.turkubusinessregion.com

70



1.5.2.5 EXPOPHARM 2021

At Expopharm trade fair the most important manufacturers

present the latest products they have launched. The leading

software companies display their current programs and famous

health politicians and other important representatives of the

pharma industry contribute to making the trade fair even more

exciting.

EXPOPHARM 2021, one of the continent-wide renowned trade fairs

dedicated to the pharmaceutical industry in Europe, will take place

from the 22nd to the 25th of September at the Messe Düsseldorf. As an event that constantly

gains popularity in the pharmaceutical community, every edition of the expo attracts more

and more attendants - 500 exhibitors and over 27 000 visitors have already confirmed their

participation.

EXPOPHARM 2021 will present many opportunities for experience exchange, contracting and

establishing of new companies in the market. All participants will be given a deep insight

into how manufacturers interpret the whole flow of innovations in their products.

To ensure visitors feel safe and secure here, they have prepared a Hygiene and Infection

Protection Concept together with Messe Düsseldorf on the basis of the current Coronavirus

Protection Regulation for the State of North Rhine-Westphalia. The necessary health

precautions, hygiene measures and social distancing rules for EXPOPHARM 2021 in

Dusseldorf will be ensured in this way.

Details

Date: September 22-25, 2021

Venue:

Format:

WWW:

Convention Center Düsseldorf - Düsseldorf (Germany)

Hybrid

www.expopharm.eu



71

1.5.2.6 BioJapan

BioJapan has played an important role in facilitating

interaction between Japanese and global

companies/organizations and stimulating new business

opportunities for almost two decades.

Top business development, licensing, and alliance

management professionals, R&D personnel, and biotech company executives from around the

world will gather in Yokohama in October 2021 for the 23th iteration of BioJapan. Over 1,000

Organizations from all over the world are expected to participate in the event, to hold an

anticipated 12,000 business meetings over the course of the three days. With the addition of

online meetings system, participants will be able to participate our one-on-one partnering

from all over the world.

Details

Date: October 13-15, 2021

Venue:

Format:

WWW:

Pacifico Yokohama National Convention Hall – Tokyo (Japan)

Hybrid

www.ics-expo.jp

72



1.5.2.7 BIO Europe

BIO-Europe is the largest life science partnering

conference in Europe supported by the

Biotechnology Industry Organization. The conference provides B2B partnering platform to

its participants and attracts a wide range of business leaders, including senior executives of

leading biotech companies, business development teams from large and midsize

pharmaceutical companies, investors and other industry experts.

BIO-Europe conference is organized by EBD Group – the leading partnering firm for the

global life science industry. Since 1993, biotech, pharma and medical device companies have

leveraged EBD Group’s partnering conferences, technology and services to identify business

opportunities and develop strategic relationships essential to their success. EBD Group’s

sophisticated web-based partnering service, partneringONE, is used as the partnering engine

at numerous third-party events around the world.

Details

Date: October 25-28, 2021

Venue:

Format:

WWW:

Stockholm (Sweden)

Digital | Hybrid

www.informaconnect.com



73

1.5.2.8 CPhI Worldwide

CPhI is an established pharmaceutical event

with over 30 years' experience of bringing

together the movers and shakers in pharma.

Uniting niche and top buyers and sellers

together under one roof in nine event

locations around the world, CPhI hosts

quality conferences, free seminars, Awards and even pharma community charity expeditions.

Each year CPhI unites more than 100,000 pharmaceutical professionals through exhibitions,

conferences and online communities to network, identify business opportunities and expand

the global market. Hosting events in Europe, China, Korea, India, Japan, South East Asia,

Middle East and North America, CPhI co-locates with ICSE for contract services, P-MEC for

machinery, equipment and technology, InnoPack for pharmaceutical packaging, BioLIVE for

biopharma and FDF for every aspect of the finished dosage supply chain.

Details

Date: November 9-11, 2021

Venue:

Format:

WWW:

Fiera Milano – Milan (Italy)

Hybrid

www.cphi.com

74



1.5.2.9 MEDICA

MEDICA is the world’s largest event for the medical sector. For

more than 40 years it has been firmly established on every

expert’s calendar. The event is the largest medical trade fair in

the world – it attracts several thousand exhibitors from more than

50 countries in the halls.

Each year, leading individuals from the fields of business,

research, international experts, decision-makers from different

sectors and politics visit this trade fair. An extensive exhibition

and an ambitious program — which together present the entire

spectrum of innovations for outpatient and clinical care — await everyone interested in

Düsseldorf.

Details

Date: November 15-18, 2021

Venue:

Format:

WWW:

Convention Center Düsseldorf - Düsseldorf (Germany)

Hybrid

www.medica-tradefair.com



75

1.5.2.10 INTERPHEX Japan 2021

INTERPEHX JAPAN is Japan's largest exhibition

for pharmaceutical and cosmetics

manufacturing/packaging technologies. With 23

years of history, INTERPHEX JAPAN is known as the best business platform to network with

industry top leaders from pharmaceutical and cosmetics industry in Japan and Asia. The show

is held inside INTERPEHX Week Tokyo - Asia's leading comprehensive pharma and cosmetics

event.

INTERPHEX Week Tokyo consists of 4 exhibitions for pharmaceutical technologies —

INTERPHEX JAPAN (Manufacturing & Packaging), in-PHARMA JAPAN (APIs/ Pharmaceutical

Ingredients), BioPharma Expo (Biopharmaceutical) and PharmaLab Japan: formerly BIOtech

Japan (Drug Discovery).

Details

Date: December 8-10, 2021

Venue:

Format:

WWW:

Javits Center – Tokyo (Japan)

Hybrid

www.interphex.jp

76



1.5.3 National events

1.5.3.1 APTEKA

authorities.

APTEKA is a priority exhibition in Russia that brings together

all pharmaceutical industry participants: manufacturers and

distributors of medicines and medical products,

representatives of pharmacies and pharmacy chains, medical

practitioners, new drug developers, and healthcare

APTEKA trade fair is part of the Russian Healthcare Week International Scientific and

Practical Forum, which includes a series of exhibition and congress events of medical and

pharmaceutical subjects, assembling the medical community from all over Russia.

During the exhibition visitors will see how the Russian pharmacy retail market is organized

and participants will have an opportunity to demonstrate new products for the Russian

pharmacy retail, enter the Russian consumer market through pharmacy chains, find exclusive

Russian manufacturers of medicines, medical products for retail in the pharmacy chains of

one’s region and find unique Russian providers for digital solutions and related services for

one’s pharmacy business.

Details

Date: March 2-4, 2021

Venue:

Format:

WWW:

Danilovsky Event Hall – Moscow (Russia)

Hybrid

www.aptekaexpo.ru



77

1.5.3.2 IPhEB Russia

IPhEB Russia is a key event in the Russian pharmaceutical

market, a platform for effective negotiations with clients

of leading Russian and foreign pharmaceutical and

biotechnological companies from all over the world.

IPhEB Russia aims to become a unique platform for

meeting business leaders and experts from the pharmaceutical and biotechnology industries,

investors, government officials and heads of leading research and educational centers from

around the world.

The IPhEB focuses on developing effective solutions for the active development of domestic

innovative products in the pharmaceutical and biotechnological industries and increasing the

investment attractiveness of the region. The event is supported by the Ministry of Industry

and Trade of the Russian Federation.

Details

Date: April 14-17, 2021

Venue:

Format:

WWW:

Expoforum – St. Petersburg (Russia)

Hybrid

www.gotoipheb.com

78



1.5.3.3 BIOTechMed

BioTechMed is the key platform for discussion of current

problems in biomedicine and for dialogue between

government and business, which defines the future

development of the industry. The event includes the

professional networking platform and scientific

conference with the event space of an exposition.

BioTechMed aims to create and promote interest in

synergy between members of the market for the transition to healthcare of a new

technological structure and to form a common understanding of the problems, goals, and

capabilities of this field.

Details

Date: October 2021

Venue:

Format:

WWW:

Hotel Primorie - Gelendzhik (Russia)

Hybrid

www.biotechmedconf.ru



79

1.6 Clusters and associations

1.6.1 Association of pharmaceutical manufacturers of Eurasian

Economic Union

Association of pharmaceutical manufacturers of Eurasian Economic Union was registered in

2012. The Association includes leading full cycle manufacturing companies, such as

Pharmstandard PJSC, Biocad CJSC, Geropharm Company group, Nanolek LLC, STPC Polysan

LLC, Active Komponent CJSC, Generium JSC, ChemRar CVT, Nativita LLC.

Association coordinates business activities of its members - pharmaceutical manufacturers of

the Eurasian Economic Union involved in the manufacture of medicines. Also, Association

protects and represents of common interests of its members by implementing the following

activities:

§ Assistance in achieving compliance with Good Manufacturing Practice (GMP) rules by

members of the Association;

§ Support of medical supply to the population, medical and preventive institutions,

§ Development of the pharmaceutical market of the EEU member countries;

§ Promotion of scientific research in the field of circulation of medicines

Contact information

Testovskaia Str., 10 – CJSC "North Tower"


INN: 7730185068

office@spmeeu.ru | www.spmeeu.ru

80



1.6.2 Union of Medical and Pharmaceutical Projects. XXI Century

"Medical and Pharmaceutical Projects. XXI Century" is non-commercial partnership in the

sphere of development, production and circulation of medicines and medical equipment. The

union was established in St. Petersburg in 2011 as a cluster organization in order to attract

investments for cluster development and support of cluster projects.

The partnership is the main coordinator of companies-members of the medical and

pharmaceutical industry cluster. The Partnership brings together manufacturing companies,

educational and scientific institutions, which are able to represent a wide range of services

for the development of medical and pharmaceutical industry.

In 2012 the Partnership became one of the winners of the best programs for development of

innovative territorial clusters selection in the Russian Federation. Competitive selection of

cluster programs was conducted by Working Group on development of public-private

partnership in the innovation sphere under the Government Commission on high

technologies and innovations.

The partnership was established in order to protect the rights and legitimate interests of

participants in the implementation of major investment projects, as well as to form and

promote development of key cluster projects in the manufacturing, educational and

scientific fields, to develop market of pharmaceutical industry and increase the investment

attractiveness of the region.

Contact information

Nevskii pr., 146 lit. A, premises 6N


INN: 7842290127

http://21mpp.ru/



81

1.6.3 Cluster of medical, environmental instrumentation and

biotechnology

The Cluster of medical, environmental instrumentation and biotechnology was formed in

2005, bringing together small and medium-sized Russian enterprises that have been working

in medical instrumentation for more than 20 years. Enterprises-members of the cluster have

common interests in industrial cooperation and joint promotion of products to the Russian

and foreign markets. Mutual interests stimulate formation of an alliance of voluntary and

equal high-tech and innovative companies.

The main product line of the companies-members of the cluster is R&D developments

transformed into a serial production. Russian and foreign patents bring innovation into their

developments. Production is highly competitive on foreign markets, including European and

North American markets. Quality of production is confirmed by several certificates: ISO, CE,

FDA.

From 2005 to 2019, the number of enterprises-members of the cluster increased from 12 to

141. The total volume of sales reached 14.8 billion rubles; the number of employees of the

companies became more than 18,600 people. Cluster residents export their production to 98

countries.

Contact information

Petrogradskaia emb., 34 lit. B


INN: 7813205110

info@clustermedtech.ru | www.clustermedtech.ru

82



1.6.4 Professional Association of Pharmaceutical Workers

Association is a public organization which admits only pharmacists as members. The goal of

the Association is to protect the professional interests of pharmaceutical professionals.

Specialists need advice on various issues but do not have enough professional information.

Specialists-members of the Association have the following opportunities:

§ Support during the passing periodic accreditation;

§ Attendance of free classes at the School of Pharmacy and get information about new

medicines;

§ Attendance of various free seminars, conferences, participation in webinars conducted

by Association, accredited in the system of continuous medical and pharmaceutical

education;

§ Opportunity to apply to the Association labor exchange and get assistance in finding a

job;

§ Free consultation of the pharmacist-adviser on pharmaceutical activities;

§ Free advice from a lawyer on legal and HR issues related to protection of rights;

§ Recommendations for assignment of a qualification category;

§ Opportunity to receive a petition for awarding insignia.

Contact information

Vladimirskii pr., 17


INN: 7841015209

fa@farmass.spb.ru | www.fa-spb.ru



83

1.7 Cases and success stories

1.7.1 BIOCAD

BIOCAD is one of the largest international innovative

biotechnology companies in Russia, uniting world-class

research centers, modern pharmaceutical and

biotechnological production, preclinical and clinical

studies that meet international standards. BIOCAD

carries out a full cycle of drug development: from the search for a molecule to mass

production and marketing. The company focuses on drugs for the treatment of oncological,

autoimmune and infectious diseases, and also works in the field of therapy for other socially

significant diseases.

BIOCAD has created an international group of companies in Belarus, Ukraine, Brazil, China,

India and the USA. Biosimilars and innovative MABNEXT products in the BIOCAD product

range are in demand both in actively developing markets and in developed countries. The

company is interested in expanding its presence in the countries of the CIS and Southeast

Asia, certain countries of the Middle East and North Africa, South America and China, Europe

and the USA.

BIOCAD plans to enter the European Union market through a comprehensive development

program in Finland. In 2017, the company signed a cooperation agreement with the

pharmaceutical cluster of Turku Science Park, the University of Turku and the Abo Academy.

The company plans to build a plant for chemical and biological products in the Finnish city of

Turku. The plant will cover an area of over 3.5 thousand square meters. The planned

investments are expected to exceed EUR 25 million, the project implementation term is 7

years.

BIOCAD has prepared a portfolio of products for the European markets containing seven

molecules for the treatment of oncological and autoimmune diseases: melanoma, breast

cancer, stomach cancer, kidney cancer, lung cancer, rheumatoid arthritis and multiple

sclerosis.

1.7.2 CYTOMED

Medico-biological research-production complex

“CYTOMED” (MBSPC “CYTOMED”) is an innovative

scientific-production pharmaceutical company. Now

the company has about 10 patented innovative

medicines for the prevention and treatment of influenza, acute respiratory infections,

immunodeficiency therapy, inflammatory processes, restoring human reproductive health,

etc.

84



In 2015, MBSPC “CYTOMED” launched the production of Russian medicines for influenza and

ARVI treatment in Finland at the new CYTOMED OY plant. The decision to build a new plant

was made by the company back in 2011. Construction was completed in June 2012.

The plant's capacity is 12 million packs of finished pharmaceutical products per year. The

production facilities of the enterprise occupy about 400 sq. m, warehouses – another 600

sq. m. The company has invested more than RUB 1 billion in the purchase of a land plot,

construction and repair, and the purchase of equipment. Construction of a plant of this level

connects Russian enterprises to the European healthcare system. Compliance of production

with the GMP standard allows to freely sell Russian-made products in European and world

markets.

1.7.3 BIOPHARMOS

BIOPHARMOS has been specializing in industrial

biotechnological cultivation of cells of rare medicinal

plants since 1987.

The research center of the group carries out patenting,

testing and certification of products on the territory of

the Russian Federation and the European Union and is a member of the Skolkovo Innovation

Center.

In 2012, a subsidiary company of BIOPHARMOS, Pharmbiotech Oy, was registered in Finland.

The company acquired an industrial complex with an area of 3 thousand sq. m for

EUR 1 million, with the possibility of further expansion by 1.5 times. In 2014, the company

launched biotechnological production of biomass of rare plants for medical and food

industries in the Finnish port city of Hamina. The approximate amount of investments is 2

million euros.



85

1.8 Information sources

1.8.1 Strategic planning documents

§ Order of the Ministry of Industry and Trade of the Russian Federation of October 23,

2009 No. 965 “On approval of the Strategy for the development of the pharmaceutical

industry of the Russian Federation for the period until 2020”

§ Draft order of the Government of the Russian Federation “On approval of the Strategy

for the development of the pharmaceutical industry of the Russian Federation for the

period up to 2030” (published in 2018)

1.8.2 Legislative acts

§ Federal Law of April 12, 2010 No. 61-FZ “On Circulation of Medicines”

§ Decree of the President of the Russian Federation of May 7, 2018 No. 204 “On national

goals and strategic objectives of the development of the Russian Federation for the

period up to 2024”

§ Decree of the President of the Russian Federation of March 17, 2020 No. 187 “On retail

trade of medicinal products for medical use”

§ Decree of the Government of the Russian Federation of February 17, 2011 No. 91 “On the

federal target program “Development of the pharmaceutical and medical industry of the

Russian Federation for the period up to 2020 and further perspective”

§ Decree of the Government of the Russian Federation of April 15, 2014 No. 305 “On

approval of the state program of the Russian Federation "Development of the

pharmaceutical and medical industry” for 2013-2020”

§ Decree of the Government of the Russian Federation of December 14, 2018 No. 1556 “On

approval of the Regulation on the system for monitoring the circulation of medicinal

products for medical use”


particular issues related to the circulation of medical devices, including state registration

of a series (batch) of a medical device”


particular issues related to the circulation of medicinal products for medical use, which

are intended for use in conditions of the threat of occurrence, occurrence and

management of an emergency and for organizing the provision of medical assistance to

persons affected by emergencies, prevention of emergency situations, prevention and

treatment of diseases that pose danger to others, diseases and injuries resulting from

exposure to adverse chemical, biological, radiation factors”

86



§ Decree of the Government of the Russian Federation of May 16, 2020 No. 697 “On

approval of the Rules for issuing a permit for retail sale of medicinal products for

medical use in the remote mode, the implementation of such sale and delivery of these

medicinal products to citizens and amending some acts of the Government of the Russian

Federation on the issue of remote retail trade of medicinal products for medical use”

§ Resolution of the Government of the Russian Federation of June 30, 2020 No. 955 “On

particular issues related to putting medicinal products for medical use into civil

circulation”

§ Decree of the Government of the Russian Federation of November 2, 2020 No. 1779 “On

Amendments to the Regulation on the system for monitoring the circulation of medicinal

products for medical use”

§ Decree of the Government of the Russian Federation of December 21, 2020 No. 2187 “On

approval of the Rules for the provision in 2021 of grants in the form of subsidies from the

federal budget to budgetary institutions for the implementation of projects for the

development of medicinal products and medical devices”

§ Decree of the Government of the Russian Federation of January 28, 2021 No. 60 “On

Amending Clause 32 of the Regulation on the system for monitoring the circulation of

medicines for medical use”

1.8.3 Statistics

§ Federal Customs Service

www.customs.gov.ru

§ Federal State Statistics Service (Rosstat)

www.rosstat.gov.ru

§ Department of the Federal State Statistics Service for St. Petersburg and Leningrad

Region (Petrostat)

www.petrostat.gks.ru

§ Analytical portal “Export of Regions” of JSC “Russian Export Center”

www.regionstat.exportcenter.ru

1.8.4 Research and reviews

§ Baker McKenzie. Promoting Medical Products Globally. Handbook of Pharma and

MedTech Compliance. Russia

§ Baker McKenzie. Pharmaceuticals & Healthcare Russia. Legal Alert. March 2020. New

Measures Related to Supply of Medicines and Medical Devices due to Spread of COVID-19

§ DSM Group. Analytical report “Russian pharmaceutical market. Results of 2017”





87


§ National Rating Agency. Analytical survey “Pharmaceutical market of the Russian

Federation – will the state help us?”

§ Deloitte CIS Research Center “Trends of the pharmaceutical market – 2020”

88



2 PART 2: EXPORT DIRECTORY

2.1 ACTICOMP

Company profile

Acticomp is a pharmaceutical company that specializes in

development and production of active pharmaceutical

ingredients (API) using the latest technologies and equipment.

The company was founded by a group of specialists in

pharmaceuticals in St. Petersburg.

Acticomp combines its efforts with many leading Russian and

foreign pharmaceutical companies in order to provide people

with locally produced medicines in various fields of medicine

(cardiological, antiviral, antibiotics).

Acticomp’s team work is based on flexibility, competence,

experience and rigorous standards of quality.

Products and services

The company produces the following main product groups:

§ Substances;

§ Rapid COVID-19 antigen test;

§ Rapid test for antibodies to COVID-19.

Key figures:

Founded: 11.06.2002

Turnover (2020): 2 010,325 mln. RUB

Employees (2020): 240

INN: 7817041279

Type of company: medium-sized enterprise

Product code: 21.10 Manufacturing of

pharmaceutical substances

Contact information:

Doroga na Metallostroi 5A,

Metallostroi village


+7 (812) 457 11 11

info@acticomp.ru

https://acticomp.ru/

Contact person: Semenova Inna – General

Director



89

2.2 ALKOR BIO

Company profile

The St. Petersburg company Alkor Bio was founded in 1992.

Nowadays the company evolved into the largest in St. Petersburg

region biotechnological holding consisting of several companies.

Alkor Bio Holding is widely known as the leading domestic

manufacturer and supplier of reagent kits for hormonal

diagnostics, determination of tumor markers, infection diseases

diagnostics, allergo diagnostics, control materials for

immunoassay, reagent kits and enzymes for molecular-genetic

analysis.

A successfully developing area of the company is diagnostics of

genetic predisposition to multifactorial diseases. The company's

product catalog includes more than 80 items of test systems and

more than 1,000 items of reagents and enzymes.



§ Reagent kits and test systems for ELISA;

§ ELISA equipment;

§ Reagent kits for allergy diagnostics;

§ Products for DNA-microchip diagnostics;

§ Products for PCR diagnosis;

§ Antigens;

§ Monoclonal antibodies by order;

§ Software.

Key figures:

Founded: 21.12.2006

Turnover (2020): 995,155 mln. RUB


INN: 7838370980


Product code: 21.20 Production of

medicines and materials used for medical

purposes


Zheleznodorozhnyi pr., 40A, office 217


+7 (812) 677 87 79

info@alkorbio.ru

https://www.alkorbio.ru/

Contact person: Polyntsev Dmitrii – General

Director

90



2.3 ALLOPHARM

Company profile

Chernysh Sergei – Doctor of biology, member of the Russian

Academy of Natural Sciences, head of the laboratory of

biopharmacology and immunology of insects in St. Petersburg

State University is the founder and ideological inspirer of the

company. Allopharm is engaged in the search for, development

and commercialization of new medicinal substances, the

prototypes of which are based on the active components of insect

immune systems, with antiviral, antitumor and antibacterial

action. Some of the preparations developed by the company,

obtained through complete chemical synthesis or biosynthesis in

insect cultures, have already found application in medicine and

dermatocosmetology.

Allopharm’s most promising developments are based on

fundamental research carried out by the employees of the

laboratory of biopharmacology and immunology of insects at the

Entomology Department of St. Petersburg State University.


The company develops new medicinal substances used in various

preparations:

§ Antiviral and antineoplastic drugs;

§ Antimicrobial drugs;

§ Antibacterial drugs and wound dressings;

§ Products for vaccines.

Key figures:

Founded: 17.05.2004


Employees (2020): 5

INN: 7801265876

Type of company: micro enterprise

Product code: 46.45.1 Wholesale trade in

perfumes and cosmetics, except for soap


Malyi Prospect V.O., 57/4 lit. Zh, premises 8-

N, office 1.3.1B


+7 (931) 592 33 75

office@allomedin.ru

https://allopharm.ru/

Contact person: Shevchenko Olga – General

Director



91

2.4 AMBER

Company profile

Amber Group of companies was founded in 2006 in St. Petersburg.

The company specializes in scientific developments in

biotechnology, molecular biology, pharmacology and medical

genetics. A full cycle of preclinical pharmaceutical studies is

carried out on the basis of own vivarium of the company. Amber

group has a fully equipped molecular genetic laboratory and

vivarium in St. Petersburg.

During 12 years the company carried out about 50 R&D projects of

different complexity, developed about 70 diagnostic PCR sets,

produced a number of strains of human (animal) proteins, created

a number of unique methods, prepared a federal target program

and organized pilot production of bioseparation cartridges for

DNA isolation.


The company provides services in the following areas:

§ Conducting preclinical studies;

§ Development of PCR kits;

§ Sequencing;

§ Recombinant protein synthesis.

Key figures:

Founded: 21.12.2006


Employees (2020): -

INN: 7816403840


Product code: 72.19 Scientific research and

development in natural and technical

sciences


Budapeshtskaia Str., 63-1, 29


+7 (911) 731 85 98

ambergroup@mail.ru

https://www.amber-genetics.com/

Contact person: Startsev Veniamin– General

Director

92



2.5 ASSOCIATION OF MEDICINE AND ANALYTICS

Company profile

Association of Medicine and Analytics (AMA) is one of the largest

companies in Russia specializing in development, production and

sales of gastroenterological diagnostic equipment. AMA spares

neither time nor resources for development of its own scientific

bases and production. Innovative diagnostic technologies

developed by the company and highly qualified personnel provide

high market positions and contribute to the overall development

of medical diagnostics not only in Russia, but also abroad.

The AMA trademark is registered by the International Bureau of

the World Intellectual Property Organization (WIPO) in

accordance with the Madrid Agreement and Protocol. The

geography of registration will extend not only to Russia and the

CIS, but also to the countries of the European Community and

Asia.


The main activity of the company is development and production

of test systems for rapid and accurate diagnosis of Helicobacter

pylori infection and various pathological diseases of the

gastrointestinal tract.

Key figures:

Founded: 04.12.2002



INN: 7801223114

Type of company: small enterprise

Product code: 26.60.5 Manufacturing of

diagnostic and therapeutic equipment for

medical purposes


17 Line V.O. 4-6


+7 (812) 380 76 99

info@amamed.ru

http://www.amamed.ru/

Contact person: Dmitrienko Marina –

General Director



93

2.6 AVENA

Company profile

Avena company conducts research of properties of different

probiotics, mainly - bacterium Enterococcus faecium L3, and

realizes production of therapeutic and prophylactic products on

its basis. These products are aimed to restore natural human

microflora and help with dysbiosis and a huge list of diseases and

conditions, connected with it.

The science team of the company brings together microbiologists

and physicians under the guidance of corresponding member of

the Russian Academy of Sciences, Professor Alexander Suvorov.

The company also conducts clinical trials in leading clinics in St.

Petersburg and Moscow: North-Western State Medical University

named after I.I. Mechnikov, St. Petersburg State Pediatric Medical

University, The Pavlov First St. Petersburg State Medical

University, Scientific Research Institute of Nutrition, etc.


The company produces original and generic drugs to combat the

following groups of diseases:

§ Gastroenterological diseases;

§ Infectious diseases;

§ Cancer and other diseases.

Key figures:

Founded: 13.12.2001


Employees (2020): 4

INN: 7802182990



pharmaceuticals


Srednegavanskii pr., 3 flat 2


+7 (812) 438 76 57

mail@avena.ru

https://avena.ru/

Contact person: Alekhina Galina – Director

94



2.7 BALTPHARMA

Company profile

Baltpharma is a company developing and implementing modern

technologies of active pharmaceutical ingredients synthesis on

the basis of traditional chemical synthesis and breakthrough

technologies. Flexible approach to organization, combination of

conventional and breakthrough technologies allows to reach the

required level of competences and competitive ability in

compliance with modern international quality standards.

On the basis of modern chemical synthesis technologies

Baltpharma will provide a wide range of active ingredients, giving

significant price reduction, reduction of technological and

engineering implementation period.

The goal of Baltpharma is to satisfy at most extent needs of the

Russian market in high-technology products in full compliance

with international standards and to create sufficient

technological basis for global market entry.


The company operates in the following key areas:

§ Production of chemicals and active pharmaceutical

substances;

§ Technological engineering and preparation for

technology transfer;

§ Production of small batches of pharmaceutical substances

and finished dosage forms for preclinical and clinical

trials and registration purposes;

§ Introduction of breakthrough technologies for the

synthesis of APIs using micro- and milireactors;

§ Development of technological regulations and the

introduction of high-tech equipment for the synthesis of

chemicals;

§ Development of laboratory and pilot technologies for

cleaning API.

Key figures:

Founded: 18.08.2016



INN: 7838057960





Doroga v Kamenku, 74 lit. A, room 202


+7 (812) 320 00 38

info@baltpharma.com

https://baltpharma.com/

Contact person: Golant Zakhar – General

Director



95

2.8 BELKOZIN

Company profile

Belkozin pharmaceutical research and production center in St.

Petersburg has been operating since 2013. The company produces

medical products based on natural protein - collagen. Medical

products are sponges with the addition of various medical

ingredients.

The company's team of employees is versatile, disciplined and

focused on efficiency. Employees are well educated, apply modern

methods of work, constantly improve their professional level and

implement new technologies in production.


The company produces the following types of products:

§ Collagen hemostatic sponge;

§ Stimul-OSS Dental sponge;

§ Thrombocol Spongy plate;

§ Meturacol Sponge for wound closure.

Key figures:

Founded: 21.05.2013


Employees (2020): 7

INN: 7802826250

Type of company: large enterprise




8 Verkhniy lane, 4


+7 (981) 721 10 27

krasiy@fnpc.ru

http://fnpc.ru/

Contact person: Shpilevoi Mikhail – General

Director

96



2.9 BIC

Company profile

Basic Individual Complex (BIC) is a dynamically developing

research and production company operating in the Russian

market. The manufacturing platform of the company is located in

St. Petersburg and equipped with high-tech equipment. Products

are manufactured in accordance with modern complex approach

to quality assurance and control of raw materials and finished

products. The food safety management system in production,

packing, storage and delivery of EUBICOR and EUBICOR KROSHKA

meets the requirements of State Standard GOST R ISO 22000-2007.

BIC company has won the contest "The best enterprise for the

production of health products - 2013" held by the St. Petersburg

Pharmaceutical Association in "Sales Leader" category. Products

of the company are manufactured from natural ingredients.

EUBICOR KROSHKA brand is classified as 100% organic.


The company develops and produces biologically active food

supplements, food and cosmetic products under the EUBICOR

brand.

Key figures:

Founded: 10.02.2011



INN: 7810815928





Kurliandskaia Str., 28 lit. A,

premises 16-N, section 34


+7 (812) 240 17 61

info@npk-bik.ru

https://eubikor.ru/

Contact person: Gaiypova Natalia – General

Director



97

2.10 BIOCAD

Company profile

Biocad is one of the largest international innovative

biotechnology companies in Russia, combining world-class

research centers, modern pharmaceutical and biotechnology

production, preclinical and clinical trials that meet international

standards. The company employs about 2,500 people, almost a

third of them are scientists and researchers.

Biocad leads the full cycle of drug development: from molecule

search to mass production and marketing. The product portfolio

includes 60 registered medications, 20 of which are biological.

More than 25 other products are in various stages of

development.

Biocad maintains high product quality, improves technologies

and optimizes processes, expanding its activities beyond Russia.

Biocad has created an international group of companies in

Belarus, Ukraine, Brazil, China, India and the US.




§ Oncological diseases;


§ Autoimmune disease.

Key figures:

Founded: 25.06.2001

Turnover (2020): 34 168,444 mln. RUB

Employees (2020): -

INN: 5024048000



pharmaceuticals


Sviazi Str., 34 lit. A

Strelna village


+7 (812) 380 49 33

biocad@biocad.ru

https://biocad.ru/

Contact person: Morozov Dmitrii – General

Director

98



2.11 BIOFABRIKA

Company profile

St. Petersburg company “Biofabrika” is the only licensed

manufacturer of Medicinal Leech in the North-West region of

Russia. The pharmaceutical company operates under the

international GMP standard, which ensures high quality of the

production process.

For years of activity Biofabrika has become a reliable supplier for

the largest pharmacy networks, research institutes, city multiprofile

hospitals, clinics, medical centers, doctors of private

practice in St. Petersburg, Russia and Europe. Since 2003 the

company has launched innovative production of cosmetics under

the “Hiruline Laboratory” brand name. Since 2005 Biofabrika

started supplying laboratory medical leeches to Europe: Germany,

Switzerland, England, France, Spain and to Israel.


The main activity of the company is the production and supply of

medical leeches.

Key figures:

Founded: 03.01.1996


Employees (2020): 5

INN: 7810686077





Maslianyi lane 8


+7 (800) 222 56 56

dir@lenbiofarm.ru

https://lenbiofarm.ru/

Contact person: Dusaeva Olesia – General

Director



99

2.12 BIOPHARMOS

Company profile

BioPharmos Group is a leading European company in industrial

biotechnological cultivation of cells of rare medicinal plants.

The group's facilities are located in St. Petersburg (Russia) and

Kotka (Finland) and are certified according to international

quality standards ISO 9001:2015 and ISO 22000:2005 (HACCP).

The group's R&D center provides patenting, testing and

certification of products in the Russian Federation and the

European Union. The company is also a member of the Skolkovo

Innovation Center.

In 2012, BioPharmos Group was awarded the European Grand

Prize for Quality (Grand Prix Européen de la Qualité) in the

category "Leader in Biotechnology innovations application".




§ Meteorological dependence and cardiovascular diseases;

§ Complications during pregnancy;

§ Infection diseases and flu;

§ Metabolic disorders;

§ Dysfunctional changes in the female reproductive system

and others.

Key figures:

Founded: 15.12.2008


Employees (2020): 1

INN: 7802456930




sciences


Engels pr., 27 lit. Zh


+7 (999) 044 68 63

info@bioconstructor.ru

https://bioconstructor.ru/

Contact person: Kotin Oleg – General

Director

100



2.13 BIOSURF

Company profile

Biosurf was founded in November 1999. Initially, the core of the

company was formed by the employees of the Medical

Biotechnology Department of the Central research

rentgenoradiological institute of the Ministry of Healthcare:

biotechnologists, pharmacologists, biochemists, physiologists,

morphologists and process engineers who had extensive

experience in the creation and production of liposome and

emulsion products. Employees of the company are highly

qualified specialists with a wide range of knowledge and practical

skills in analytical and preparative chemistry of proteins, nucleic

acids and lipids.

During the time, the Biosurf team expanded with specialists who

have experience in the organization of pharmaceutical production

based on the requirements of GMP. In December 2013, Biosurf

received a perpetual license for the production of

organopreparations. The production structure also includes

quality control laboratory.


The main activity of the company is the production of the

«Surfactant-BL» medication, as well as studying the use of the

drug for new indications. The drug was developed for the

treatment respiratory distress syndrome (ARDS) in newborns and

is included in the Temporary Methodological Recommendations

"Prevention, Diagnosis and Treatment of New Coronavirus

Infection" of the Russian Ministry of Healthcare.

Key figures:

Founded: 29.11.1999


Employees (2020): 7

INN: 7826711145





Sytninskaia Str., 14 lit. B, premises 1-N


+7 (812) 596 87 87

info@biosurf.ru

https://www.biosurf.ru/

Contact person: Prepialov Aleksandr –

General Director



101

2.14 BIOTECH

Company profile

Biotech Research and Production Company is the developer of

Roncoleukinum medicament. In 2005 and 2008 the company was

awarded with gold medals at the international specialized

exhibition "The World of Biotechnology" for the development of

genetically engineered immunocorrector Roncoleukinum.

Structure of Biotech includes production, marketing and sales

departments, and also scientific programs in medicine and

veterinary medicine department. Production of genetically

engineered medicines is conducted by highly qualified employees,

including candidates of biological, technical and chemical

sciences. Products are manufactured on modern high-tech

equipment and is carried out on the area of

1000 m 2 .




§ Neurology and ENT diseases;



§ Gynecological diseases, etc.

Key figures:

Founded: 25.01.2013



INN: 7819317204



pharmaceuticals


Sankt-Petersburgkii pr., 60 lit. A, office 328

Peterhof


+7 (812) 603 27 98

biotech@biotech.spb.ru

https://biotech.spb.ru/m/

Contact person: Iakovleva Vera – General

Director

102



2.15 BIOVITRUM

Company profile

BioVitrum company operates on the Russian market of medical

and laboratory equipment. More than 10 years of active work

made the company a world leading manufacturer of diagnostic

equipment and medical consumables. The company opened

offices in major cities of Russia and Kazakhstan, expanded the

network of regional offices, launched its own production and built

all internal business processes of the company.

Efficiency, accuracy and speed of diagnostics, safety in equipment

operations are the key factors that company is guided by when

choosing foreign partners. The concept of modern and reliable

equipment distribution makes it possible to implement the main

idea of the company - saving lives with diagnostics. BioVitrum is a

leader in implementation of the largest federal programs in the

history of healthcare - "Modernization of Healthcare" and

"Oncology".


The company manufactures drugs for combating diseases in the

following industries:

§ Morphology;

§ Microbiology;

§ Molecular and cell biology.

Key figures:

Founded: 29.09.2011



INN: 7801557131


Product code: 46.90 Non-specialized

wholesale trade


Bolshoi Prospekt V.O. 68 lit. A

199106, St. Petersburg, Russia

+7 (812) 305 06 06

zakaz@biovitrum.ru

http://www.biovitrum.ru/

Contact person: Zinoviev Oleg – General

Director



103

2.16 CYTOMED

Company profile

Cytomed is an innovative scientific and manufacturing

pharmaceutical company and was founded in 1989. The company

develops and conducts clinical practice implementation of

original medications based on scientific research on peptides that

affect the human body. Peptides are specific biologically active

substances extracted from various animal organs and tissues

(brain, thymus and pineal glands, spleen, gastrointestinal tract,

etc.).

Presently, the company offers a range of about 10 patented

innovative medical products, designed for prophylaxis and

treatment of influenza, acute respiratory diseases and

inflammatory processes, immunomodulation therapy,

reproductive health restoration, etc.

Cytomed works in accordance with international GMP (Good

Manufacturing Practice) standards, has its own scientific

laboratory complex and production facilities in Finland

(CYTOMED OY) and St. Petersburg on the territory of

Novoorlovskaya special economic zone.


The company produces the following key groups of drugs:

§ Vartocid;

§ Prostatilen;

§ Prostatilen AC;

§ Thymogen;

§ Cytovir-3.

Key figures:

Founded: 31.05.1993



INN: 4700000042



pharmaceuticals


Orlovo-Denisovskii pr., 14 building 1


+7 (812) 602 05 93

https://cytomed.ru/

Contact person: Khromov Aleksandr –

General director

104



2.17 DIOD

Company profile

Diod company is considered to be the founder of natural nondrugs

market in Russia. The main activities of the company are

development and production of natural non-drug and medicinal

products, therapeutic cosmetics, medical and ecological

equipment, innovative substances aimed to prevent and treat

socially significant diseases.

Clinical and preclinical studies of the products are carried out

jointly with the largest scientific institutes, centers and clinics:

State research center for therapy and preventive medicine, A.N.

Bakulev National medical research center of cardiovascular

surgery, Institute of aviation and space medicine, National

medical research radiological centre, Kirov military medical

academy, N.N. Burdenko main military clinical hospital and

others.

Diod takes an active part in state programs aimed at forming a

healthy lifestyle. Together with a number of public organizations,

the company tries to form in the minds of Russians a culture of

responsibility for their own health.


The company manufactures the following types of products:

§ Dietary supplements;

§ Pharmaceuticals, including Hypoxen, Orvirem, Mebix;

§ Therapeutic (active) cosmetics.

Key figures:

Founded: 22.02.1993



INN: 7725024805



food supplements


Derbenevskaia Str., 11 lit. A, building 13,

room 4


+7 (499) 235 77 80

info@diod.ru

http://www.diod.ru/

Contact person: Tikhonov Vladimir –

General Director



105

2.18 EKVUS

Company profile

“Ekvus” Research and production association produces and

supplies reagents, consumables and equipment for

microbiological, medical and clean room laboratories. The list of

supplied products includes petri dishes, containers for biomateria

collection and much more.

During the period from 2014 to 2017 the company managed to

implement 1,456 projects. In 2017 Ekvus became the youngest

agency to receive GH Awards.


The company produces the following types of products:

§ Enterobiasis kits;

§ Medical masks;

§ Cotton-gauze, silicone, and cellulose swabs;

§ Reagents for microbiology;

§ Instruments and accessories for microbiology and

bacteriology.

Key figures:

Founded: 14.11.2012


Employees (2020): 4

INN: 7839471099





Obvodnyi Channel emb., 136/5 building 1,

floor 1-2 premises 10N


+7 (812) 642 57 58

sale2@medica-info.ru

https://www.xn--b1apwh1c.xn--p1ai/

Contact person: Lobanov Stanislav –

General director

106



2.19 ELEST

Company profile

The scientific-manufacturing company Elest was founded in 1991

in St. Petersburg. Today Elest is one of the leading Russian

producers of biotechnological products in medicine and

agriculture. In the healthcare market company sells dietary

supplements under "GIO-Norma" and "Phoenix" brands. The

mission of the company is to create ecological medicines and

technologies.

The company is managed by a board of directors consisting of

Professor Mark Malkov and Tatiana Dankova, PhD in economics.

Qualified specialists, including doctors and PhDs in sciences,

biotechnology, microbiology, biochemistry, chemical synthesis,

veterinary medicine and zoo technology work in the research

department of the company.

Elest holds 20 patents for world-class inventions and has massive

experience of mutually beneficial cooperation with leading

Russian research centers and foreign partners.


The company produces the following key product groups:

§ Vitamin-mineral mixtures;

§ Medicines on the basis of microbiological synthesis;

§ Feeds with regulatory properties for farm animals.

Key figures:

Founded: 03.02.2015



INN: 7811163270


Product code: 10.91.3 Production of

microbiological feed protein, premixes,

feed vitamins, antibiotics, amino acids and

enzymes


Zheleznodorozhnyi pr., 45


+7 (812) 334 59 44

elestelest@yandex.ru

http://www.elestbio.ru/

Contact person: Dankova Tatiana – General

director



107

2.20 FARMAKOGEN

Company profile

Farmakogen Center for preclinical studies plans and conducts

studies on efficiency and safety of original and reproduced

medicines prior to their clinical studies and State registration.

The company has its own vivarium and diagnostic laboratory.

Farmakogen is accredited for compliance with GLP standard,

studies are conducted in strict accordance with GOST 33044-2014,

principles of proper laboratory practice and the Order of the

Ministry of Healthcare from April 1, 2016 № 199n "Approval of

the rules of proper laboratory practice".

Employees performing key functions in the studies and involved

in the quality assurance service, has received advanced training

meeting the GLP standard at Scientific Centre for Expert

Evaluation of Medical Products.


The company provides services for preclinical, pharmacokinetic

and toxicological studies, in vivo and in vitro studies, services to

assess generative toxicity of drugs and analysis of the ability to

cause gene mutations and chromosome aberrations.

Key figures:

Founded: 27.06.2011


Employees (2020): 7

INN: 7819314027




sciences


Veteranov pr., 26 lit. A, flat 1


+7 (812) 929 20 49

fmgen@fmgen.ru

http://fmgen.ru/

Contact person: Zakharov Mikhail – General

director

108



2.21 FARMAMED.RF

Company profile

The Russian company Farmamed.RF produces finished medicines

and pharmaceutical substances. The company conducts research

on the basis of its own laboratory in the synthesis of new

medicines and search for new dosage forms. In April 2015,

Farmamed.RF successfully passed the state certification of

pharmaceutical production under the international GMP

standard.

Farmamed.RF is one of the few Russian companies producing full

synthesis of high quality active pharmaceutical substances. The

company is licensed to produce pharmaceutical substances by

methods of isolation from sources of chemical, biological, animal

and plant origin and by methods of biotechnological and chemical

synthesis. The company has received numerous awards for high

quality performance in its professional activities.


The company produces finished forms and number of

pharmaceutical substances, including the following types:

§ Emoxypine;

§ Unithiol;

§ Meldonium;

§ Methylaethylpiridinolum hydrochloride.

Key figures:

Founded: 26.11.2002


Employees (2020): -

INN: 7802201882



pharmaceuticals


Domostroitelnaia Str., 16 lit. E premises 2


+7 (812) 647 02 46

+7 (812) 596 34 28

info@farmamedspb.ru

https://farmamedspb.ru/

Contact person: Gomzhin Andrei – General

director



109

2.22 FRAMEBIOTEK

Company profile

Framebiotek is an innovative new-generation Russian

biotechnology company founded in 2020. Framebiotek is focused

on providing partners with an opportunity to use the full

functionality of the R&D department in industrial biotechnology

on a turnkey basis.

Framebiotek has created a platform for the full cycle

development of innovative and import-substituting biotech

medicines - from development of product life cycle ideas and

design of molecules and strains to technology transfer with

issuance of documents and necessary actions for state

registration.

The general laws of organization of biological systems allow

Framebiotek development platforms and expertise to be used for

a wide range of industrial biotechnology and chemistry areas.

These platforms are based at the intersection of biology,

chemistry, physics and engineering.


The company offers the following services:

§ Project management and maintenance;

§ Molecular genetics;

§ Microbiology and cell technologies;

§ Extraction and purification;

§ Analytics;

§ In vivo researches;

§ Technology transfer.

Key figures:

Founded: 10.09.2020


Employees (2020): -

INN: 7840093451




sciences


Rubinsteina 32 lit. A premises 24-N/office 2


+7 (911) 987 57 27

t.nemankin@framebiotek.ru

https://framebiotek.ru/

Contact person: Nemankin Timofei –

General director

110



2.23 GEMATEK

Company profile

The German company B. Braun ("Gematek" LLC) is one of the

world leaders in manufacturing of products for the healthcare

industry. The company occupies a leading position in the supply

of medical equipment for Russian medical institutions.

Today B. Brown employs almost 700 workers all over Russia, the

company is represented in almost 50 regions of the country. B.

Brown is the largest supplier of infusion pumps in Russia. The

company pays special attention to its own production on the

territory of the Russian Federation. Gematek plant, located in

Tver region, is included in the list of the country's largest

manufacturers of infusion solutions.


The company manufactures products for the following medical

directions:

§ Infusion therapy;

§ Regional anesthesia;

§ Enuresis and urology;

§ Neurosurgery;

§ Drainage and urology;

§ Spinal surgery;

§ Preventing of hospital-acquired infection;

§ Orthopedics;

§ Vascular therapy and others.

Key figures:

Founded: 21.06.2003



INN: 7714317800



pharmaceuticals


18-linia V.O., 29 lit. Z, premises 29-N/19


+7 (812) 320 40 04

office.spb.ru@bbraun.com

https://www.bbraun.ru/ru.html

Contact person: Zaharcheko Maksim -

General Director



111

2.24 GEROPHARM

Company profile

Geropharm is a national manufacturer of biotechnological drugs,

ensuring drug safety of Russia. The company was founded in 2001

and today is a large and effective business structure, one of the

significant players on the Russian pharmaceutical market and an

expert in the professional community.

Geropharm implements projects under Federal targeted support

programs of the Ministry of Industry and Trade and the Ministry

of Education and Science of the Russian Federation. In the

framework of “Pharma-2020” program Geropharm launched

Russia's only full cycle industrial production of genetically

engineered insulin from synthesis of substances to finished

dosage forms. Production is located in Obolensk (Moscow region).



directions:

§ Endocrinology;

§ Neurology;

§ Ophthalmology;

§ Gynecology.

Key figures:

Founded: 09.02.2000



INN: 7826043970





Zvenigorodskaya Str., 9


+7 (812) 703 79 75

inform@geropharm.ru

https://www.geropharm.ru/

Contact person: Rodionov Petr - General

Director

112



2.25 GOMEOFARM

Company profile

“Gomeopaticheskaia Farmatsia” (Gomeofarm) is a Russian

manufacturer of homeopathic medicines. The company was

founded in 1998 on the basis of three oldest homeopathic

pharmacies in St. Petersburg. Medicines of the company are made

from ecologically pure products of plants, animals and minerals

origin. Using years of experience and prescriptions of famous

homeopaths, Gomeofarm produces medicines that are essential in

the home medicine cabinet of every family.

Today, Gomeofarm is an industrial manufacturer of medicines, a

network of homeopathic pharmacies, homeopathic medical center

and homeopathic medical office.




§ Allergies and skin diseases;

§ Otorhinolaryngological and respiratory system diseases;

§ Diseases of the nervous system;

§ Diseases of the rectum;

§ Diseases of the cardio-vascular system and others.

Key figures:

Founded: 03.07.1998



INN: 7825696769



pharmaceuticals


Svechnoi lane 7


+7 (812) 764 24 55

https://gomeofarm.ru/

Contact person: Gakkel Vasilii – General

Director



113

2.26 GROTEX

Company profile

Solopharm ("Grotex" LLC) is the largest pharmaceutical company,

the leader in the production of liquid medicines in Russia.

Solopharm was founded in 2010 to provide Russian consumers

with affordable medicines.

Plant of the company was built in 2013 for production of liquid

sterile medicines in accordance with international quality

standards GMP using clean room technology. The plant is

equipped with modern high-tech European equipment, the latest

heating, ventilation and water treatment systems. Modern

equipment allows company to diversify products and produce

medicines in unique packaging without preservatives.

Solopharm has its own R&D department and laboratories, which

provide full-cycle pharmaceutical development and quality

control of incoming raw materials at all stages of production and

output products.



directions:

§ Ophthalmology;

§ Otorhinolaryngology;

§ Pulmonology;

§ Neurology;

§ Therapy;

§ Cosmetology and others.

Key figures:

Founded: 21.02.2010

Turnover (2020): 12 571,931 mln. RUB

Employees (2020): 1 207

INN: 7814459396





Industrialnyi pr., 71/2 lit. A


+7 (812) 385 47 87

+7 (812) 385 47 83

grtx@grotexmed.com

https://solopharm.com/

Contact person: Zherebtsov Oleg - General

Director

114



2.27 GRUNDLAGE

Company profile

"Grundlage" is a Russian manufacturer of high-quality medical

products. The company has been manufacturing personal

protective equipment since 2013. Medical masks, respirators and

protective suits are especially relevant during the pandemic and

are in high demand.

Due to modern production technologies, high-quality imported

raw materials and multi-level control system, the company

guarantees high quality, favorable prices and the best conditions

for cooperation.

The quality of manufactured products is confirmed by

international certificates. The production area of "Grundlage"

company occupies 500 m 2 . Warehouse space occupies 1,500 m 2 .

Enterprise "IntelMed" is a partner and the official distributor of

Grundlage products.


The main activity of the company is manufacturing of a wide

range of surgical and diagnostic, latex and synthetic, powder-free

and powdered medical gloves.

Key figures:

Founded: 29.10.2013


Employees (2020): 6

INN: 7843316794



materials used for medical purposes


Novgorodskaia Str., 23 lit. A, premises 98-N,

office 222


+7(812) 627-14-17

info@grundlage.info

https://www.grundlage.info/

Contact person: Vishnevskii Andrei -

General Director



115

2.28 HARMS

Company profile

History of the company began in the 90’s – the period of renewal

of views to the development of Russia and the formation of

market relations. The aim of the company is the development and

industrial use of modern technologies for the extraction of

natural components from plant sources in order to improve the

quality of human life.

Strict quality policy ensured the company recognition in the

domestic market of the EASC and became the key factor in

successful entry into international markets. Today quality

management system «HARMS» (PHARMS) is certified in

accordance with the international standard ISO 9001: 2015 (GOST

R ISO 9001: 2015).

The production of pharmaceutical substances (API) is carried out

on the basis of the License of the Ministry of Industry and Trade

of Russia and its concordance with the Rules of Good

Manufacturing Practice (GMP) is confirmed by the Conclusion.


The company manufactures the following product groups:

§ Pharmaceutical substances (API);

§ Dry extracts (DSI);

§ Dry herbal infusions.

Key figures:

Founded: 30.07.1992


Employees (2020): 0

INN: 7815023002





Aleksandra Nevskogo Str., 9 lit. G, premises

25n-26


+7 (812) 327 07 76

office@pharms.ru

https://www.pharms.ru/

Contact person: Ermakov Sergei – General

director

116



2.29 KEM

Company profile

Research and production company “KEM” has a policy aimed at

creating an efficient and safe production, maintaining high

quality standards in production of pharmaceutical substances.

The company uses possibilities of modern technology, high

potential of domestic science and has 10 years of experience in

developing of organic synthesis technology.

KEM is aimed at the development of knowledge-intensive

technologies and their use in the production of substances. The

organization of pharmaceutical substance production allows to

provide the necessary raw materials to pharmaceutical plants in

Russia for the production of finished drugs.

KEM production capacities are located in modern complex on the

territory of Kuzmolovskii village in Leningrad region. Production

facilities are equipped with modern domestic and foreign

technological equipment. Compliance with standards in the

production process is constantly monitored by quality control

laboratory.


The company manufactures a wide range of chemical and

pharmaceutical substances on demand.

Key figures:

Founded: 21.03.2006



INN: 7838348688




purposes


Zavodskaia Str., 3/142

Kuzmolovskii gorodskoi poselok


+7 (812) 702 19 92

mail@npfkem.ru

http://www.npfkem.ru/

Contact person: Mikhailov Vladimir -

General Director



117

2.30 LEKKER

Company profile

The history of the company began in 2000. Vladimir Denisov -

General Director of the company and physiotherapist with wide

practice, aimed to make the use of antiseptics more convenient

for consumers. Vladimir registered his first device and launched

Lekker manufacturing company.

Through years of work the company has come a long way from the

creating a prototype to the organizing of serial. All necessary

tests have been conducted and all necessary permissions from the

Ministry of Healthcare of the Russian Federation were obtained.

Over time, the company began to produce not only medical, but

also cosmetic products. Today products of Lekker company are

sold in all regions and cities of Russia, from Kaliningrad to

Vladivostok. Medical and cosmetic products registered by Lekker

company are among the leaders in the antiseptic market.



§ Medical products;

§ Cosmetics;

§ Formagrif products;

§ Household chemicals;

§ Sanitizers.

Key figures:

Founded: 11.10.2000



INN: 7801162366



medical instruments and equipment


Zelenkov lane 6 lit. A, corp., 1, premises 11


+7 (812) 448 54 65

help_gendir@lekker.ru

https://lekker.ru/

Contact person: Denisov Vladimir - General

Director

118



2.31 MEDPOLYMER

Company profile

Medpolymer is the first industrial enterprise for manufacturing

medical products in the USSR, tracing its history back to the

artificial dentistry and dental cements factory of the Leningrad

Plant named after M.V. Lomonosov. The plant was founded by

Order of the People's Commissariat of Healthcare of the RSFSR on

December 17, 1935 and went into operation on April 16, 1937.

Today, the company continues manufacturing medical products,

but the production of infusion solutions has become a priority.

Medpolymer is the largest producer of infusion solutions in the

Northwest region of Russia. Currently, production capacity is

more than 35 million polymer containers of multi-layer polyolefin

a year. Medpolymer cooperates with many research institutes and

participates in development of new medicines.


The company produces the following product groups:

§ Infusion solutions;

§ Medical devices.

Key figures:

Founded: 16.11.1992



INN: 7806008745



pharmaceuticals


Revolyutsii highway, 69


+7 (812) 520 64 00

medpolymer@medp.spb.ru

https://medp.spb.ru/



119

2.32 NEPHRON

Company profile

Research and production company Nephron is the first domestic

manufacturer of concentrated hemodialysis solutions and

disinfectants for hemodialysis. The company is also supplier of

consumables for most networks of private dialysis centers in the

Russian Federation. Along with sales in Russia, the company has

experience in supplying to the CIS countries: since 2007 products

are supplied to Kazakhstan, since 2010 to Ukraine and Tajikistan,

since 2011 to Belarus.

Nephron is a winner of the "Made in St. Petersburg" contest and

the winner of the "Made in Russia" contest. The company is

equipped with more than 1 700 m² of its own production area,

where more than 300 m² are clean rooms meeting to ISO 7 and ISO

8 standards.



§ Equipment;

§ Consumables;

§ Disinfectants;

§ Concentrates;

§ Non-fabric materials.

Key figures:

Founded: 26.04.1999



INN: 7805128486



medical instruments and equipment


Kalinina Str., 13 lit. A, premises 13-N,

room 241


+7 (812) 380 88 28

office@nephron.ru

http://www.nephron.ru/

Contact person: Sapozhnikov Denis –

General Director

120



2.33 NICF

Company profile

The Research Center for Pharmacotherapy “NICF” was founded as

an independent organization in 1994 on the basis of the

Laboratory of Microbiology and Pharmacotherapy of the Soviet

research technological institute of antibiotics and medical

enzymes.

The company conducts research and development, produce and

supply materials and equipment for the needs of clinical

laboratories, primarily of microbiological profile. The

organization performs expert, advisory and methodological

functions in the field of microbiological control. Continuous

scientific search in the field of microbiological diagnostics allows

the company constantly enrich the list of output products in

accordance with the modern requirements and norms, as well as

with actual needs of microbiological laboratories.



§ Sets of indicator discs;

§ Diagnostic discs and kits;

§ Reagents and kits for microbiological diagnostics;

§ Sugars, amino acids, polyatomic alcohols for

microbiological analysis;

§ Nutrient mediums;

§ Selection additives for nutrient mediums;

§ Microbiological Supplies.

Key figures:

Founded: 07.11.2014



INN: 7816598363





Bely Kuna Str., 30 lit. A, premises 18N,

office 300


+7 (812) 327 55 81

nicf@nicf.spb.ru

http://www.nicf.spb.ru/

Contact person: Grishko Iulian – General

Director



121

2.34 NIKA

Company profile

Nika Factory ("Pink Flamingo" trade mark) is an enterprise

producing traditional and modern medical consumables for

complex treatment of skin injuries. Pink Flaming dressing

materials are used in medical institutions and occupy a worthy

place in industrial and household medicine cabinets.

Nika Factory is a pioneer in production of medical absorbent

cotton on the Russian market. In 1995, the production of

consumables was established on the technological basis of the

"Sovetskaya Zvezda" factory, the leading enterprise of the textile

industry in the USSR era.



§ medical absorbent cotton;

§ innovative bandages;

§ fixation bandage;

§ non-woven cloths;

§ alcohol swabs;

§ hydrogel products, surgical tapes.

Key figures:

Founded: 19.08.1993



INN: 7807000749



absorbent cotton from textile materials


Lifliandskaia Str., 3 lit. A, premises 5-N,

room 1


+7 (812) 252 56 11

mail@fabrika-nika.ru

https://fabrika-nika.ru/

Contact person: Slobodianiuk Nikolai –

Director

122



2.35 OMEGA PHARMA

Company profile

The Omega Pharma company has been working in the

pharmaceutical market since 2004. The company specializes in

selling high-quality dietary supplements. The main brands in the

pharmaceutical market promotion are the following products:

§ TM UNIK Omega-3;

§ «UNIK Omega-3» Russia;

§ «Calcium Omega Plus» Russia;

§ «Omega-3 and Collagen» Russia;

§ «Omega-3 and Coenzyme Q10» Russia;

§ «Omega-3 and Laminaria» Russia;

§ «Omega-3 with Lutein и Zeaxanthin» Russia;

§ «Omega-3 with Krill oil» Netherlands-Norway Rimfrost;

§ «Smart Fiber» Russia.



§ Omega-3 products;

§ Dietary fiber;

§ Piakartil.

Key figures:

Founded: 06.08.2014


Employees (2020): 3

INN: 7801635492


Product code: 46.46 Wholesale trade of

pharmaceutical products


Korablestroitelei Str., 32/3 lit. A, 116


+7 (812) 984 00 68

info@omegapharma.ru

http://omegapharma.ru/

Contact person: Pobelianskii Georgii –

General Director



123

2.36 PHARM. ASSOCIATION NAMED FOR PASTER

Company profile

"Pharm. Association named for Paster" LLC has been selling its

products under the "Zdravushka" brand since 1998. During 22

years the company has managed to sell more than 24 million

packages of products.

The fruits of “Silybum marianum” serve as the main raw material

for medicines production contain substance collectively called

"silymarin". Silymarin was studied in laboratories and clinics

around the world, where its hepatoprotective,

immunomodulatory, antioxidant qualities have been proven. The

source of silymarin are extracted meal and extract.

Silymarin has been proven to protect and restore liver cells, has a

pronounced antioxidant and immunomodulatory effect. In 2013

determination of the molecular mechanism of the antiviral action

of silymarin became a revolutionary discover. Different

researches have proved its anticancer potential. In 2018 it was

also proven that thistle oil reduces the rate of body weight gain

on a high-calorie diet.


The company manufactures various types of products made on the

basis of “Silybum marianum” fruits:

§ Extracted meals;

§ Oils;

§ Syrups;

§ Herbal tea;

§ Extracts.

Key figures:

Founded: 03.01.1996



INN: 7801092013





Manuilskogo Str., 20 lit. A

Kronstadt


8(800) 200-75-00

info@zdravushka.ru

https://www.zdravushka.ru/

Contact person: Zhmaev Sergey – General

Director

124



2.37 PHARMA GEN

Company profile

Pharma Gen is a biopharmaceutical company that develops and

manufactures original biologics for cosmetology and veterinary

medicine in accordance with GMP requirements and provides high

quality research and manufacturing services. The company was

founded in 2005 by specialists in medical genetics, molecular

biotechnology and biopharmacology.

Pharma Gen specialists have unique experience in Russia in

development and production of biologics, including their filling

into ampoules and vials and sublimated drying.

The Pharma Gen established partnership with St. Petersburg State

University, S.M. Kirov Military Medical Academy, Smorodintsev

Research Institute of Influenza, I.P. Pavlov Research Institute of

Physiology, Institute of experimental medicine, “Alloferon” LLC,

“Binnopharm” CJSC, Avir Green Hills Biotechnology AG, Novartis

International AG, etc.


The company produces medical, cosmetic and veterinary

medicines and provides services for biologics quality research,

filling biologics into ampoules or vials, and freeze-drying.

Key figures:

Founded: 17.06.2005



INN: 7838326719



chemical products, not included in other

groups


Tikhoretskii pr., 4 lit. A, premises N-3 ch.p.

50


+7 (812) 297 97 61

pharmagenreg@gmail.com

http://pharmagen.su/

Contact person: Reziapkin Aleksandr –

Director



125

2.38 PHARMA VAM

Company profile

Pharma VAM is a manufacturer of original, patent-protected

medicines that have no analogues in the world. Since 1994 the

company has conducted fundamental research in modern biology

and medicine. The method of the body's natural defenses

regulation developed by the company became the basis of a new

strategy in the treatment of infectious and non-infectious

diseases.

In the course of development, the company created a basic

regulatory molecule. It is possible to create compositions with

other medicines on the basis of this molecule in order to treat

socially significant diseases, including infectious one.

These newly created medicines compositions with pathogenetic

action of this basic regulatory molecule have great potential and

provide coordination of activity and functional integrity of vital

human organs and systems.





§ Chronic inflammatory and infectious diseases;

§ Chronic liver diseases;

§ Viral diseases and others.

Key figures:

Founded: 01.03.1991



INN: 7708111656


Product code: 46.46 Wholesale trade of

pharmaceutical products


Pskovskaia Str., 17


+7 (812) 714 10 10

info@pharmavam.ru

http://pharmavam.ru/

Contact person: Balazovskii Mark – General

director

126



2.39 PHARMACEUTICAL FACTORY OF ST. PETERSBURG

Company profile

Pharmaceutical Factory of St. Petersburg has a history dating

back to 1935. Currently, the strategic direction of the company is

production of medicines for bronchial asthma (BA) and COPD

treatment. Today the company produces "Beklospir" - the first

domestic dispensed aerosol inhaler with an active substance

beclomethasone dipropionate. The production process meets

international and national standards in pharmaceutical

manufacturing. The list of manufactured products includes more

than 100 items.

The company cooperates with the St. Petersburg State Chemical

Pharmaceutical University and work in collaboration with the

Human Brain Institute of the Russian Academy of Sciences,

Scientific Research Institute of Nutrition, Smorodintsev Research

Institute of Influenza, Research Institute of Pulmonology, S.M.

Kirov Military Medical Academy, Russian Scientific Research

Institute of traumatology and Orthopedics named after R.R.

Vreden, First Pavlov State Medical University and other major

Russian and foreign medical and pharmaceutical companies and

research centers.



§ Aerosols;

§ Solid, soft, liquid dosage forms;

§ Cosmetic products.

Key figures:

Founded: 19.01.1994



INN: 7815026980



pharmaceuticals


Moiseenko Str., 24 A


+7 (812) 271 29 88

prim@galenopharm.ru

http://www.galenopharm.ru/

Contact person: Rostokin Valery – General

director



127

2.40 PHARMAKOR PRODUCTION

Company profile

Pharmakor Production company was founded in 1998. The

company produces pharmaceutical production of the full cycle of

dietary supplements and medicines: formulation development,

registration, production.

Pharmakor Production is a two-time winner of the “Green Cross”

International Pharmaceutical Award. In 2019 the company won

awards in "Company of the Year" in "Domestic producer of dietary

supplements" nominations. In 2018 the award was given to

“Vitamores Immuno” complex in "Measures for prevention and

treatment of seasonal diseases" nomination.

Production sites undergo annual pharmaceutical audit by

European pharmaceutical manufacturers. Product quality control

is ensured at all stages of production, storage and sales in

accordance with ISO, GMP and HACCP standards.


The company manufactures products to combat the following

diseases:

§ Allergology;

§ Cardiology;

§ Diabetology;

§ Gastroenterology;

§ General therapy;

§ Neurology;

§ Obstetrics and Gynecology;

§ Oncology.

Key figures:

Founded: 19.03.1998



INN: 7802114781




purposes


Repishcheva Str., 14/5 office 247


+7 (812) 677 89 82

pharmprod@pharmprod.ru

https://pharmprod.ru/

Contact person: Novikova Elena – General

director

128



2.41 PHARMASYNTEZ-NORD

Company profile

Pharmasyntez Group of companies is one of the largest producers

of socially important medicines in Russia. Medicaments of the

company are represented in major therapeutic areas such as

tuberculosis, HIV, oncology, diabetes, hepatitis, etc. Medicine’s

portfolio includes more than 170 items. Pharmasyntez is the

leader in production of anti-tuberculosis medicines. The company

produces almost all antituberculosis drugs registered in Russia,

including medicines of new generation. The annual output is

more than 76 mln packs.

Production facilities are represented by five modern high-tech

factories in the following cities: Irkutsk, Ussuriysk, St. Petersburg,

Bratsk, Tyumen. The company guarantees stable high quality of

produced medicines. All production sites of the company comply

with the highest requirements of production organization and

quality control of GMR.




§ Tuberculosis;

§ HIV;

§ Oncology;

§ Diabetes;

§ Hepatitis;

§ COVID-19.

Key figures:

Founded: 14.05.2010



INN: 3851000490



pharmaceuticals


Doroga v Kamenku 74, premises 1-N


+7 (812) 240 45 15

info-psn@pharmasyntez.com

https://pharmasyntez.com/

Contact person: Kvasnikov Mikhail –

General director



129

2.42 PHARM-HOLDING

Company profile

Pharm-Holding is a scientific and practical division of Geropharm

group of companies responsible for medicines development. The

company was launched on the territory of the Special Economic

Zone of techno-innovative type "Neudorf" (St. Petersburg). New

laboratories of biotechnological block were created in 2014 as

part of the center to strengthen biological products department.

The research center consists of five high-tech laboratories, which

perform the full cycle medicines development from a molecule to

a finished medicament: laboratory of bioorganic chemistry,

testing analytical laboratory, medicines development laboratory,

laboratory of genetic engineering, bioprocess development

laboratory.


On the basis of laboratory facilities, the company provide tests

and analysis of medicines and produces the following main groups

of products:

§ solid dosage forms (pellets, tablets, capsules);

§ soft dosage forms (suppositories, ointments);

§ non-sterile liquid dosage forms (solutions, syrups).

Key figures:

Founded: 05.06.2006



INN: 7813348911




sciences


Sviazi Str., 34 lit. A

Strelna village


+7 (812) 493 55 01

inform@geropharm.ru

https://pharmholding.com/

Contact person: Drai Roman – Director

130



2.43 PHARMPROJECT

Company profile

Pharmproject is a private company founded by graduates of St.

Petersburg Chemical Pharmaceutical University. About 90% of the

employees are also graduates of SPCPA. The company's

production area occupies 4,500 m² where 1,500 m² is occupied by

clean rooms. The company has its own production line of soft

dosage forms for creams, ointments and gels production.

Leading specialists, experts and practicing physicians note high

quality, effectiveness and safety of the company's products. After

registration procedure and market entry, the accumulation of

evidence base for all medicinal products continues.


The company produces solid, soft and liquid dosage forms, offers

consulting services for medicines registration, development of

registration documents, obtaining a registration certificates for

medicaments, etc.

Key figures:

Founded: 09.06.2000



INN: 7801153192



pharmaceuticals


Sophiiskaia Str., 14 lit. A


+7 (812) 331 93 10

sales@pharmproject.com

http://pharmproject.com/

Contact person: Saakian Suren – Manager -

individual entrepreneur



131

2.44 PHARMSYNTHEZ

Company profile

Pharmsynthez is a Russian pharmaceutical company specializing

in the production and promotion of portfolio for innovative

medicines. The company can operate in three directions at once,

which is unique for the Russian pharmaceutical market:

laboratory research and development of new medicaments,

manufacturing of original substances and medicaments and their

market launch.

A unique specialization in production and promotion of a

portfolio of innovative medicines, as well as the ability to carry

out R&D contracts distinguish Pharmsynthez among Russian

biopharmaceutical manufacturers.

Shareholders and management of the company successfully

develop technologically complicated business with a focus on

their own unique, innovative products and see significant

perspectives both in the fast-growing pharmaceutical markets of

Russia, the CIS, the EU and the USA.




§ Tumors;

§ Glaucoma;

§ Tuberculosis and others.

Key figures:

Founded: 23.08.1999



INN: 7801075160



pharmaceuticals


Kapitolovo station 134 lit. 1

Kuzmolovskii, Vsevolozhskii district


+7 (812) 329 80 80

info@pharmsynthez.com

http://pharmsynthez.com/

Contact person: Prilezhaev Efim – General

director

132



2.45 POLYSAN

Company profile

Polysan is a pharmaceutical company operating in Russia and

Ukraine. Production capacities of the company located in St.

Petersburg.

Polysan includes a research facilities, a production corporation

and commercial service. The main activities of the company are

development, production, promotion and sales of new medicines.

The research and production laboratory is engaged in constant

development of new medicines.

The company has a preclinical and clinical research department,

which coordinates ongoing research on the bases of leading

medical and science institutions. All scientific activities are

coordinated by the Biomedical research coordination department.


The company produces the following key groups of medicines:

§ Cycloferon;

§ Cytoflavin;

§ Reamberin;

§ Remaksol.

Key figures:

Founded: 10.01.1993


Employees (2020): 1 046

INN: 7805023934



pharmaceuticals


Salova Str., 72 2 lit. A


+7 (812) 710 82 25

info@polysan.ru

https://www.polysan.ru/

Contact person: Borisov Dmitrii – General

Director



133

2.46 PPDP

Company profile

Enterprise for diagnostic medicine production ("PPDP" LLC) was

created in order to meet the needs of practical healthcare with

modern effective medicaments for diagnostics of influenza A and

B viruses and other flu diseases: parainfluenza viruses of 1, 2 and

3 types, RSV and adenoviruses. The production is based on years

of scientific research and production experience of biotechnology

laboratory and diagnostic products in the Smorodintsev Research

Institute of Influenza of the Ministry of Healthcare of Russia,

which is one of the founders of the company.

Diagnostic products developed by "PPDP" LLC are widely used in

public healthcare practice for different immunological

researches: Immunofluorescence analysis (IFL), Immunoenzyme

analysis (ELISA), hemagglutination inhibition analysis. The

company produces all the necessary range of immunodiagnostic

products. This made it possible to carry out laboratory

surveillance for influenza and acute respiratory viral infections in

Russia and CIS countries in accordance with the recommendations

of the World Health Organization (WHO).


The company produces a wide range of modern products for the

diagnosis of influenza viruses and other acute respiratory viruses,

including:

§ Fluorescent immunoglobulins for detection of viral

antigen in clinical materials;

§ Immunoenzyme test-systems for detection of viral

antigens and increase in antibodies in the sera of

returnees;

§ Diagnosticums and diagnostic sera for antibody detection

and virus identification in hemagglutination inhibition

assay and neutralization reaction;

§ Monoclonal antibodies for immunodiagnostic studies.

Key figures:

Founded: 29.07.2013


Employees (2020): 3

INN: 7813567247




purposes


Prof. Popova Str., 15/17


+7 (812) 309 85 32

ppdp@influenza.spb.ru

http://ppdp-spb.com/

Contact person: Grudinin Mikhail – General

Director

134



2.47 RADUGA LAKHTA

Company profile

Raduga Production (Raduga Lakhta, LLC) is a modern full cycle

pharmaceutical production plant. Raduga Production plant is

connected by long-term partnership with such companies as

Roche, Ipsen, KRKA, which manufacture their products at the

facilities of the plant.

Continuous improvement and striving to meet international

quality standards are priority goals for the company which allow

to expand cooperation with leading European companies. Since

2012, Raduga Production has successfully passed audits of

medicines manufacturers such as Actavis, AstraZeneca, Ipsen,

KRKA, Roche, Sandoz. Over the years, the company has

accumulated significant experience in implementing

international projects, advanced technologies with full cycle

production, control and quality assurance of the final product.


The company manufactures medicines in solid dosage forms -

tablets, capsul-coated tablets, hard gelatin capsules, and also

provides services for primary and secondary packaging of a wide

range of dosage forms, including injectable forms.

Key figures:

Founded: 18.12.2012


Employees (2020): -

INN: 7814558051





3 Konnaia Lakhta Str., 48/7, lit. A,

premises 1-N 307 rm 1


+7 (812) 324 31 86

info@raduga-production.ru

http://raduga-production.ru/

Contact person: Grigoriev Ilia – General

Director



135

2.48 RESEARCH INSTITUTE OF INNOVATIVE

TECHNOLOGIES AND MATERIALS

Company profile

The Research Institute of Innovative Technologies and Materials

has been presented on the medical device market for over 20

years. The organization conducts preclinical and clinical trials of

medical devices.


The company manufactures medical products and analytical

chemistry reagents for universal use:

§ Helicobacter pylori indicator paper;

§ Azopyram to control pre-sterilization cleaning in liquid

and dry versions;

§ Azopyram for the Gregerson’s reaction - pigments for

chromoscopy.

Key figures:

Founded: 21.03.2011


Employees (2020): 5

INN: 7802744800





Bolshoi Sampsonievskii pr., 80, 18


+7 (931) 224 96 88

+7 (921) 941 58 60

info2@niiekf.ru

https://azopiram.ru/

Contact person: Pliss Mikhail – Director

136



2.49 SAMSON-MED

Company profile

Manufacturing pharmaceutical company Samson-Med is an

innovative enterprise of full cycle production. The company

performs the full range of works from medicines research and

development to mass production and marketing support of

medicaments on the pharmaceutical market. The company has

developed and implemented a number of unique technologies for

the production of active pharmaceutical ingredients and original

domestic drugs from endocrine-enzyme raw materials.

The company manufactures finished medicines and substances on

a contract basis. For more than 15 years Samson-Med established

reliable partnership with leading Russian and foreign

pharmaceutical companies such as Nizhpharm (STADA Group,

Germany), Petrovax Pharm (Russia), Geropharm (Russia).




§ Viral diseases;


§ Inflammation diseases of the respiratory organs;

§ Heart failure and others.

Key figures:

Founded: 30.09.1999



INN: 7810173847



pharmaceuticals


Moskovskoe highway, 13


+7 (800) 100 05 54

sb@smmed.ru

https://samsonmed.ru/

Contact person: Chilaev Islam – Director



137

2.50 SEVERNAIA ZVEZDA

Company profile

Severnaia Zvezda is a dynamically developing company that has

been operating on the Russian pharmaceutical market for over 20

years. During this time the company has managed to build a

modern production of medicines and equip it in accordance to

international GMP standards.

The production structure of the company consists of the

production department "Kuzmolovo" (since 2002) and a new

separate department - production of pharmaceuticals "Nisino",

which construction began in 2012 and was finished in 2018.

Production plant "Nisino" has two production lines of tableting,

two lines of sorting and packaging and a line of sachet

production.


The company manufactures products to combat the following

diseases:

§ Dermatology;

§ Gynecology;

§ Otorhinolaryngology;

§ Cardiology;

§ Infectious diseases.

Key figures:

Founded: 20.01.1997



INN: 7720185196




purposes


Electrodnaia Str., 2/34, premises 47


+7 (800) 333 24 14

electro@ns03.ru

https://ns03.ru/

Contact person: Chuglina Elena - General

Director

138



2.51 SIBENZYME

Company profile

SibEnzyme company produces and sells nucleic acid metabolism

enzymes and related products used in molecular biological

research and genetic engineering. The company produces around

two hundred different enzymes and constantly updates and

expands product list. SibEnzyme is one of the top three producers

of restriction enzymes in the world.

The main directions of SibEnzyme scientific activity are selection

and study of a new site-specific enzymes, mainly bacterial DNA

endonucleases and DNA methyltransferases, study of eukaryotic

genomes, development of new methods to work with extended

DNA, epigenetic studies.


The company's main activity is development of new types of DNA

splitting enzymes.

Key figures:

Founded: 30.08.2005


Employees (2020): 2

INN: 7810036103


Product code: 46.90 Non-specialized

wholesale trade


Voronezhskaya Str., 5 lit. A, premises 5-N

office 120


+7 (812) 740 61 48

spb@sibenzyme.ru

http://russia.sibenzyme.com/

Contact person: Reshetnikova Galina –

Director



139

2.52 VITAL DEVELOPMENT CORPORATION

Company profile

The main purpose of Vital Development Corporation is

implementation of complex equipage of clinical and diagnostic

laboratories program. Since 2016 the Company has been

producing "Prodeion" purifying water unit to ensure achievement

of this goal. Purpose of the unit is to obtain ultrapure deionized

water suitable for all types of laboratory analysis. There is a range

of units of different productivity, which allow to choose water

purification system that meets the requirements of any customer.

In 2019, Vital Development Corporation made a breakthrough in

the market of domestic equipment for laboratory analysis by

launching producing of automatic analyzers for biochemical and

immunoturbidimetric analysis under "VitaLine" trademark. The

"VitaLine-150 Biochemical Analyzer" product won the "Best

Innovative Product 2019" award of the St. Petersburg Government

in medicine and pharmaceuticals.



§ Biochemical reagent kits;

§ Biochemistry analyzers;

§ Immunoenzymometric analysis;

§ ELISA analyzers;

§ Water purification systems and more.

Key figures:

Founded: 08.11.2010



INN: 7802730188




sciences


Doroga v Kamenku 56, lit. A


+7 (812) 702 10 86

sale@vital-spb.ru

https://www.vital-spb.ru/

Contact person: Plekhov Aleksandr -

General Director

140



2.53 WERTEKS

Company profile

Werteks JSC is a Russian pharmaceutical company that was

founded in 1999, and received its first license to medicines

manufacture in 2003. The company became the winner of the 2017

Quality Award of the Government of the Russian Federation.

Werteks was the only pharmaceutical manufacturer among 10

laureates.

Portfolio of the company includes more than 300 product items,

and specifically 5 types of original combined products for

dermatology, gynecology, otorhinolaryngology, cardiology, cold

and flu symptoms relief (have no analogues). Portfolio also

includes branded medicaments, generics and cosmetic products.

The company sells its products in more than 55,000 pharmacies in

the Russian Federation, as well as in Kazakhstan and Belarus.


The company produces drugs for combating diseases in the

following areas:

§ Gastroenterology;

§ Cardiology;

§ Neurology;

§ Oncology;

§ Ophthalmology;

§ Urology;

§ Endocrinology and others.

Key figures:

Founded: 07.12.1999


Employees (2020): -

INN: 7810180435



pharmaceuticals


Doroga v Kamenku, 62 lit. A


+7 (800) 200 03 05

+7 (812) 329 30 41

https://vertex.spb.ru

Contact person: Pobelianskii Georgy –

General Director



141

For notes

142



This publication includes materials protected under copyright law, the copyright for which is held by Russian - Finnish

Life Science Park. The materials appearing in publications may not be used for commercial purposes. The contents of

publications are the opinion of the writers and do not represent the official position of Russian - Finnish Life Science

Park. Russian - Finnish Life Science Park bears no responsibility for any possible damages arising from their use. The

original source must be mentioned when quoting from the materials.

© Copyright 2021 Russian - Finnish Life Sсience Park. All rights reserved.



143

144



2021. RFLSP.Russian.Finnish.Life.Science.Industry.EN

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?